

1 **Characterization of the apicomplexan amino acid transporter (ApiAT) family in**

2 ***Toxoplasma gondii***

3

4 Short Title: Amino acid transporters in *Toxoplasma* parasites

5

6 Kathryn E. R. Parker^{1,¶}, Stephen J. Fairweather^{1,¶}, Esther Rajendran^{1,¶}, Martin Blume^{2,3},

7 Malcolm J. McConville², Stefan Bröer^{1,*}, Kiaran Kirk^{1,*}, Giel G. van Dooren^{1,*}

8

9 ¹Research School of Biology, Australian National University, Canberra, ACT, 2601,

10 Australia.

11 ²Department of Biochemistry and Molecular Biology and the Bio21 Institute of Molecular

12 Science and Biotechnology, University of Melbourne, Parkville, VIC, 3010, Australia.

13 ³Robert Koch Institute, Berlin, 13353, Germany.

14

15 *Corresponding authors

16 Emails: giel.vandooren@anu.edu.au; kiaran.kirk@anu.edu.au; stefan.broeer@anu.edu.au

17 [¶]Joint first authors

18

19 **Abstract**

20 Apicomplexan parasites are auxotrophic for a range of amino acids which must be salvaged
 21 from their host cells, either through direct uptake or degradation of host proteins. Here, we
 22 describe a family of plasma membrane-localized amino acid transporters, termed the
 23 Apicomplexan Amino acid Transporters (ApiATs), that are ubiquitous in apicomplexan
 24 parasites. Functional characterization of the ApiATs of *Toxoplasma gondii* indicate that
 25 several of these transporters are important for intracellular growth of the tachyzoite stage of
 26 the parasite, which is responsible for acute infections. We demonstrate that the ApiAT
 27 protein *TgApiAT5-3* is an exchanger for aromatic and large neutral amino acids, with
 28 particular importance for L-tyrosine scavenging and amino acid homeostasis, and that
 29 *TgApiAT5-3* is critical for parasite virulence. Our data indicate that *T. gondii* expresses
 30 additional proteins involved in the uptake of aromatic amino acids, and we present a model
 31 for the uptake and homeostasis of these amino acids. Our findings identify a family of amino
 32 acid transporters in apicomplexans, and highlight the importance of amino acid scavenging
 33 for the biology of this important phylum of intracellular parasites.

34

35 **Author Summary**

36 The Apicomplexa comprise a large number of parasitic protozoa that have obligate
 37 intracellular lifestyles and cause significant human and animal diseases, including malaria,
 38 cryptosporidiosis, toxoplasmosis, coccidiosis in poultry, and various cattle fevers.
 39 Apicomplexans must scavenge essential nutrients from their hosts in order to proliferate and
 40 cause disease, including a range of amino acids. The direct uptake of these nutrients is
 41 presumed to be mediated by transporter proteins located in the plasma membrane of
 42 intracellular stages, although the identities of these proteins are poorly defined. Using a
 43 combination of bioinformatic, genetic, cell biological, and physiological approaches, we have
 44 characterized a family of plasma membrane-localized transporter proteins that we have called
 45 the Apicomplexan Amino acid Transporters (ApiATs). The family is found in apicomplexans
 46 and their closest free-living relatives. We show that *TgApiAT5-3*, a member of the family in
 47 the apicomplexan *Toxoplasma gondii*, is an exchanger for aromatic and large neutral amino
 48 acids. In particular, it is critical for uptake of tyrosine, and for parasite virulence in a mouse
 49 infection model. We conclude that ApiATs are a family of plasma membrane transporters
 50 that play crucial roles in amino acid scavenging by apicomplexan parasites.

51

52 **Introduction**

53 Apicomplexans are intracellular parasites that cause a range of diseases in humans and
 54 animals, imparting a major health and economic burden on many countries. In humans,
 55 *Plasmodium* species are the causative agents of malaria, while *Cryptosporidium* is a major
 56 cause of diarrheal disease and death in children in the developing world (1). *Toxoplasma*
 57 *gondii* can infect virtually all nucleated cells in warm-blooded animals, and is thought to
 58 chronically infect one-third of the world's human population. *T. gondii* infections are usually
 59 asymptomatic, but infection in immunocompromised patients may lead to life-threatening
 60 toxoplasmic encephalitis, and congenital toxoplasmosis may result in severe birth defects or
 61 death of the developing fetus (2).

62 A common feature of parasites is that they rely on their hosts to supply them with the
 63 nutrients necessary for their growth and replication, such as sugars, amino acids, nucleosides,
 64 and vitamins. Transporters are integral membrane proteins that facilitate the transfer of
 65 substrates across biological membranes. In apicomplexans, transporters provide the major
 66 route for the acquisition of nutrients and the removal of waste products across the plasma
 67 membrane (3), and these proteins are important for parasite survival and virulence (4, 5).
 68 Despite this, the transporters responsible for the uptake of many essential nutrients in
 69 apicomplexans have not been defined.

70 A family of Novel Putative Transporters (the NPT family) was initially identified in
 71 *Plasmodium falciparum* using a bioinformatics approach (6). The five *P. falciparum* NPT
 72 family proteins were predicted to be polytopic membrane proteins with a secondary structure
 73 characteristic of solute transporters, although they have limited sequence similarity to other
 74 eukaryotic or prokaryotic transporters. The NPT family protein *PbNPT1* localizes to the
 75 plasma membrane of the mouse malaria-causing parasite *P. berghei*, and is essential for
 76 gametocyte development in the murine host and subsequent mosquito transmission (4, 5, 7).

Other *P. berghei* NPT family proteins, *PbMFR4* and *PbMFR5*, are essential for progression through the insect stages of the life cycle, while *PbMFR2* and *PbMFR3* are important for exflagellation of male gametes and sporozoite formation, respectively, but are not essential for completion of the *P. berghei* life cycle (4). In *T. gondii*, *TgNPT1* localizes to the plasma membrane and is essential for parasite growth and virulence (5). Both *PbNPT1* and *TgNPT1* are cationic amino acid transporters, with *PbNPT1* functioning as a general cationic amino acid transporter and *TgNPT1* functioning as a selective arginine transporter (5). The functions of other NPT-family proteins are not known, although one member of the family has been associated with susceptibility to the anti-*T. gondii* drug sinefungin (8).

In this study, we have demonstrated that the NPTs are phylogenetically related, and broadly distributed within the apicomplexan phylum and their closest free-living relatives. We have characterized the NPT family proteins in *T. gondii*, demonstrating that 10 of the sixteen members of the family are expressed in the disease-causing tachyzoite stage of the parasite, and that the majority of these localize to the parasite plasma membrane. We have demonstrated that at least three of these proteins are important for *in vitro* growth of the parasite. Using a combination of genetic, physiological and heterologous expression approaches, we have shown that one of the previously uncharacterized *T. gondii* NPT-family members transports aromatic and large neutral amino acids, and that this transporter is particularly important for the uptake of tyrosine into the parasite. We conclude that NPTs are a family of amino acid transporter proteins found in apicomplexans, and we propose that the family be renamed the Apicomplexan Amino acid Transporter (ApiAT) family.

98

99 Results

ApiATs are broadly-distributed in apicomplexan parasites. To identify ApiAT-family proteins in the apicomplexan parasites *T. gondii*, *Neospora caninum*, *Eimeria tenella*, *P. falciparum*, *P. berghei*, *Theileria annulata*, *Babesia bovis* and *Cryptosporidium parvum*, we undertook Basic Local Alignment Search Tool (BLAST) searches using *PbNPT1* as an initial query sequence (www.eupathdb.org; (9)) We also undertook BLAST searches of the genomes from the chromerids *Chromera velia* and *Vitrella brassicaformis*, which are close free-living relatives of apicomplexans (10), and a broad range of other eukaryotes (www.eupathdb.org, www.blast.ncbi.nlm.nih.gov; (9, 11)). In addition to the previously described five *Plasmodium* ApiAT family proteins, we identified sixteen ApiAT family proteins in both *T. gondii* and *N. caninum*, nine in *E. tenella*, six in *T. annulata*, five in *B. bovis*, three in *V. brassicaformis*, and one each in *C. parvum* and *C. velia* (Fig S1). Using this strategy, we were unable to identify ApiAT family proteins outside of the apicomplexan/chromerid lineage. Using *PbNPT1* as a search query in profile hidden Markov Model searches, we identified the LAT3 and LAT4 proteins from humans (<http://hmmer.org>; (12); Fig S2). LAT3 and LAT4 are members of the SLC43 family of the major facilitator superfamily of transporters, and mediate the transport of branched chain and other large neutral amino acids (13).

To determine the relationships between ApiAT family proteins, we constructed a multiple sequence alignment. This revealed the presence of a major facilitator superfamily (MFS) signature sequence between transmembrane domains 2 and 3 of most ApiAT family protein (Fig S1; (14, 15)). Most ApiAT proteins were predicted to be polytopic membrane proteins containing 12 transmembrane domains (www.cbs.dtu.dk/services/TMHMM/; (16)), and exhibited highest sequence similarity in the regions encompassing these transmembrane domains (Fig S1). These analyses are consistent with previous studies and protein database

annotations placing members of the ApiAT family into the major facilitator superfamily of transporters (5, 6).

We next performed a maximum likelihood phylogenetic analysis. This revealed the presence of multiple ApiAT subfamilies (Fig 1). Orthologs of the ApiAT2 subfamily were present in all organisms in the study, with the exception of *Cryptosporidium parvum* and the free living Chromerid species (Fig 1). Members of the ApiAT3, ApiAT5, ApiAT6 and ApiAT7 subfamilies were restricted to coccidians (a group of apicomplexans that includes *T. gondii* and *N. caninum*), and the ApiAT9 family was restricted to the piroplasms *T. annulata* and *B. bovis* (Fig 1). *Plasmodium* ApiAT3 branched with the coccidian ApiAT3 subfamily, although bootstrap support for this association was weak (Fig 1). The ApiAT8 subfamily comprises two members in each *Plasmodium* species examined. This family includes the previously described cationic transporter *PbNPT1* (here annotated as *PbApiAT8-1*). Although similar in function to the *T. gondii* arginine transporter *TgApiAT1* (previously *TgNPT1*), *PbApiAT8-1* and *TgApiAT1* appear not to be orthologous.

***T. gondii* ApiATs localize to the parasite periphery.** Previous studies demonstrated that the *P. berghei* ApiAT8-1 protein (previously *PbNPT1*) localized to the periphery of the parasite (likely to the plasma membrane), and that the *T. gondii* ApiAT1 protein (previously *TgNPT1*) localized to the plasma membrane (5, 7). To determine the expression pattern and localization of ApiAT family proteins in *T. gondii*, we introduced a hemagglutinin (HA) tag into the 3' end of the open reading frame of the remaining fifteen ApiAT genes (Fig S3A-B).

Western blotting indicated that *TgApiAT2*, *TgApiAT3-1*, *TgApiAT3-2*, *TgApiAT3-3*, *TgApiAT5-3*, *TgApiAT6-1*, *TgApiAT6-2*, *TgApiAT6-3*, and *TgApiAT7-2* proteins were expressed in tachyzoite stage parasites (Fig 2A-E). We were unable to detect expression of

TgApiAT5-1, TgApiAT5-2, TgApiAT5-4, TgApiAT5-5, TgApiAT5-6 and TgApiAT7-1.

Immunofluorescence assays (IFAs) demonstrated that *TgApiAT2, TgApiAT3-1, TgApiAT3-*

2, TgApiAT3-3, TgApiAT5-3, TgApiAT6-1 (as reported previously; (17)), and *TgApiAT6-3*

localized to parasite periphery, overlapping with the plasma membrane marker P30 (Fig 2F-

I). *TgApiAT3-3* showed additional localization to the trans-Golgi network (Fig 2G).

Although detectable by western blotting (Fig 2D-E), we could not detect *TgApiAT6-3* or

TgApiAT7-2 by IFA, possibly because the level of expression of these proteins was below

the detection limits of IFAs. We conclude that ten of the sixteen *TgApiAT* proteins are

expressed in the tachyzoite stage of *T. gondii*, and those with detectable expression by IFA all

localize to the plasma membrane of the parasite.

To determine the importance of *TgApiATs* for parasite growth, we attempted to genetically

disrupt all sixteen *T. gondii* *ApiATs* using a CRISPR/Cas9-based approach (18). Using this

strategy, we were able to disrupt fifteen of the sixteen *TgApiAT* genes (Table S1). *TgApiAT1*

could only be disrupted when parasites were grown in excess arginine, as described

previously (5). We were unable to generate frameshift mutations in *TgApiAT6-1* after

screening 12 clones from three separate transfections of a guide RNA targeting the

TgApiAT6-1 locus. Of these clones, two had a 3 bp insertion and one had a 3 bp deletion,

indicating that the guide RNA was capable of targeting the *TgApiAT6-1* locus (Table S1).

To determine which *TgApiATs* were important for parasite growth, we performed plaque

assays on each of the *TgApiAT* knockout ($\Delta apiAT$) lines grown in human foreskin fibroblasts

(HFFs) and cultured in Dulbecco's modified Eagle's medium (DMEM). Compared to

parental wild type (WT) controls, we observed greatly reduced plaque sizes in the $\Delta apiAT2$

and $\Delta apiAT5-3$ strains (Fig 3). As described previously (5), no plaques were observed in the

$\Delta apiAT1$ strain grown in DMEM (containing 400 μ M L-arginine) but normal growth of this

strain was observed when grown in Roswell Park Memorial Institute 1640 (RPMI) medium

(containing 1.15 mM L-Arg; Fig 3A). By contrast, the remaining 12 $\Delta apiAT$ lines exhibited plaques that were similar in size to WT controls (Fig 3). To test whether the growth defect in the $\Delta apiAT2$ strain was due specifically to disruption of the *TgApiAT2* locus, we complemented $\Delta apiAT2$ with constitutively expressed *TgApiAT2*. This restored parasite growth (Fig 3B). These results indicate that *TgApiAT1*, *TgApiAT2* and *TgApiAT5-3* are required for normal intracellular growth of *T. gondii* in standard *in vitro* culture conditions.

***TgApiAT5-3* is important for amino acid homeostasis in *T. gondii*.** *TgApiAT* proteins that are important for parasite growth are likely to have critical roles in nutrient acquisition. In the remainder of this manuscript, we focus on one such protein, *TgApiAT5-3*. Our previous study of *TgApiAT1* and *PbApiAT8-1* indicated a key role for these transporters in cationic amino acid uptake (5), and we hypothesized that *TgApiAT5-3* could also function as an amino acid transporter. To investigate this possibility, we incubated WT and $\Delta apiAT5-3$ parasites in medium containing a mixture of [^{13}C]-labelled amino acids for 15 mins. Polar metabolites were extracted from parasite lysates and analyzed by GC-MS. These analyses were used to quantitate the levels of intracellular amino acids and determine the extent of labeling with exogenous amino acids based on [^{13}C]-enrichment in each of the two strains. Strikingly, both the abundance and fractional labelling of [^{13}C]-L-tyrosine (L-Tyr) was reduced significantly in the $\Delta apiAT5-3$ strain (Fig 4). Abundance and fractional labeling of a number of other [^{13}C]-amino acids were altered significantly in the $\Delta apiAT5-3$ strain, although none to the same extent as L-Tyr (Fig 4). These data indicate that *TgApiAT5-3* is important for amino acid homeostasis, playing a key role in the uptake of L-Tyr into the parasite.

***TgApiAT5-3* is an aromatic and large neutral amino acid uniporter with exchange**

activity. To characterize the substrate specificity of *TgApiAT5-3* further, we expressed HA-tagged *TgApiAT5-3* in *Xenopus laevis* oocytes, and confirmed its expression and plasma membrane localization by western blotting (Fig S4A). Given the GC-MS data implicating *TgApiAT5-3* in L-Tyr uptake (Fig 4), we hypothesised that *TgApiAT5-3* transports L-Tyr. We compared the uptake of radiolabelled [^{14}C]-tyrosine ([^{14}C]Tyr) into oocytes expressing *TgApiAT5-3* relative to uninjected oocytes. Under the conditions of the experiment, there was a significant, 7-fold increase in the initial uptake rate of [^{14}C]Tyr into oocytes expressing *TgApiAT5-3* compared to uninjected control oocytes (Fig 5A).

While loss of *TgApiAT5-3* led to reduced uptake of [^{13}C]-tyrosine, levels of ^{13}C enrichment in some other amino acids increased (Fig 4). This gave rise to the possibility that *TgApiAT5-3* has exchange activity. To investigate this, we tested whether the uptake of [^{14}C]Tyr was stimulated by the presence of amino acids on the *trans* side of the membrane (i.e. *inside* the oocyte). Following preliminary experiments to optimise the preloading of L-Tyr into oocytes (not shown), we measured [^{14}C]Tyr uptake over 2 hr at an extracellular concentration of 1 mM L-Tyr in *TgApiAT5-3*-injected or uninjected oocytes that had been pre-loaded in medium containing 2.5 mM unlabelled L-Tyr. The initial rate of [^{14}C]Tyr uptake in *TgApiAT5-3*-expressing oocytes preloaded with L-Tyr was 3-fold higher than in *TgApiAT5-3*-expressed oocytes that were not pre-loaded (Fig 5B), indicating that L-Tyr uptake into *TgApiAT5-3*-expressing oocytes was stimulated by L-Tyr on the *trans* side of the membrane. We next tested whether L-Tyr efflux was also *trans*-stimulated. We preloaded *TgApiAT5-3*-expressing and uninjected oocytes with 1 mM [^{14}C]Tyr and measured the efflux and retention of the radiolabel upon the addition of 2.5 mM unlabelled L-Tyr to the external medium. [^{14}C]Tyr efflux was increased, and [^{14}C]Tyr retention reduced, in *TgApiAT5-3*-expressing oocytes exposed to 2.5 mM L-Tyr compared to those in external medium lacking L-Tyr (Fig

5C). Nevertheless, we still observed some [^{14}C]Tyr efflux over time in the absence of *trans*- substrate (Fig 5C). We observed no differences in [^{14}C]Tyr efflux or retention in control uninjected oocytes upon incubation of oocytes in 2.5 mM L-Tyr compared to incubation in buffer lacking L-Tyr (Fig S4B). These data indicate that the transporter operates more effectively under ‘exchange conditions’ than under conditions in which it is mediating a unidirectional flux.

To examine the exchange activity of *TgApiAT5-3* further, we investigated the kinetic properties of L-Tyr transport in more detail. Steady-state kinetic parameters for exchangers must be conducted at different *trans*- and *cis*-substrate concentrations to determine accurate $K_{0.5}$ values (19). We examined uptake kinetics of [^{14}C]Tyr following the preloading of oocytes with different L-Tyr concentrations (note that this, and all subsequent, uptake measurements were conducted over 10 min, representing the approximate initial rate conditions for substrate influx; Fig 5B). Both Michaelis-Menten analysis (not shown) and Scatchard linear regressions (Fig 5D) demonstrated that the apparent $K_{0.5}$ values for L-Tyr uptake into oocytes was unaffected by the cytosolic L-Tyr concentration. The gradients of fitted Scatchard plots are negative reciprocals of the apparent $K_{0.5}$ and, therefore, equivalent slopes reflect similar apparent transport affinities. $K_{0.5}$ values were consistent for both Scatchard and Michaelis-Menten plots derived from the same data, ranging from 0.25 to 0.40 μM (Table 1). As expected for *trans*-stimulated uptake, maximum rate (V_{max}) values increased in proportion to the concentration of preloaded L-Tyr (Fig 5D; Table 1).

Table 1: Michaelis-Menten kinetic parameters for the initial rate of L-Tyr uptake by *TgApiAT5-3*¹

[L-Tyr] _{trans} (mM)	Scatchard Linear Regression		Michaelis-Menten Plot	
	K _{0.5} (μM)	V _{max} (pmol/min × oocyte)	K _{0.5} (μM)	V _{max} (pmol/min × oocyte)
0	0.36	5.23	0.37	5.43
0.02	0.37	5.70	0.31	6.06
0.08	0.38	6.25	0.29	7.91
0.15	0.34	9.13	0.25	8.93
0.44	0.40	18.83	0.32	15.98
1.78	0.39	29.25	0.36	27.0

¹ Values are based on the experiment shown in Fig 5D.

To assess whether *TgApiAT5-3* activity might function as an ion:amino acid co-transporter, we conducted systematic ion-replacement uptake experiments as described previously (5). We observed no significant change in [¹⁴C]Tyr uptake under any ion-replacement conditions, suggesting that the transporter does not co-transport any of the ions tested (Fig S4C). To determine whether *TgApiAT5-3* is an electrogenic transporter (as is the case for *TgApiAT1*; (5)), we perfused oocytes expressing *TgApiAT5-3* with L-Tyr and measured currents using a two-electrode voltage clamp configuration. We observed no net current movement, including under conditions in which the membrane potential and pH gradient across the membrane were altered (Fig S4D). Together, these data indicate that L-Tyr transport by *TgApiAT5-3* does not co-transport any charged species.

Incubation of WT and Δ *apiAT5-3* parasites in a [¹³C]-amino acid mix resulted in significant increases or decreases in the ¹³C-labelling of several amino acids (Fig 4), suggesting that *TgApiAT5-3* may transport a range of amino acids. To investigate the substrate specificity of *TgApiAT5-3* further, we measured the uptake of 500 μM [¹⁴C]Tyr in oocytes expressing *TgApiAT5-3* in the presence of equimolar amounts of other unlabelled L-amino acids on the

cis side of the membrane. Only unlabelled L-tryptophan (L-Trp) resulted in a significant inhibition of L-Tyr uptake under the conditions tested (Fig S5A). To examine the *trans*-stimulated influx specificity of *TgApiAT5-3*, we pre-injected mixtures of L-amino acids and other metabolites into oocytes expressing *TgApiAT5-3*, then measured uptake of [14 C]Tyr. *TgApiAT5-3*-mediated [14 C]Tyr uptake was *trans*-stimulated by pre-injected mixtures of L-amino acids, but not amino acid derivatives, D-amino acids, nucleotides, nitrogenous bases, or sugars (Fig S5B; Table S2). To identify which amino acids might be responsible for this *trans*-stimulation, we systematically pre-injected oocytes expressing *TgApiAT5-3* with 5 mM of each of the 20 proteinogenic amino acids in the mixture (with the exception of L-Tyr which was preloaded to equilibrium), before measuring *trans*-stimulated uptake of [14 C]Tyr. We found that aromatic and large neutral amino acids, but not smaller or charged amino acids, *trans*-stimulated [14 C]Tyr uptake (Fig 6A).

We tested the uptake of a range of [14 C]-labelled aromatic and large neutral amino acids, including L-Trp, L-histidine (L-His), L-phenylalanine (L-Phe), L-leucine (L-Leu) and L-isoleucine (L-Ile) into oocytes expressing *TgApiAT5-3*. In the absence of a *trans* substrate, the rate of uptake of aromatic and large neutral amino acids were significantly increased compared to uninjected oocytes (1.7-fold increase for L-Trp, 3.1-fold increase for L-His, 5.5-fold increase for L-Phe, 2.2-fold increase for L-Leu, and 2.4-fold increase for L-Ile; Fig S5C). The uptake of the cationic amino acid L-Arg did not differ between *TgApiAT5-3* injected and uninjected oocytes (Fig S5C). As was seen for L-Tyr, uptake of the tested aromatic and large neutral amino acids was *trans*-stimulated by aromatic and large neutral amino acids, and not by smaller or charged L-amino acids (Fig 6A). The uptake of L-Arg was not *trans*-stimulated by any of the amino acids tested (Fig 6A). We next measured efflux of preloaded [14 C]-labelled L-Tyr, L-Trp, L-His, L-Phe and L-Leu in the presence of all 20 proteinogenic amino acids in the extracellular medium. We observed the same substrate

specificity, with aromatic and large neutral L-amino acids stimulating the efflux of the [¹⁴C]-labelled substrates tested (Fig 6B).

From the experiments conducted in this section, we conclude that *TgApiAT5-3* can mediate the transport of aromatic and large neutral amino acids. The transporter can function as a uniporter, but has a strong propensity for exchange, implying a role for *TgApiAT5-3* in the homeostasis of a range of aromatic and large neutral amino acids.

***TgApiAT5-3* is important for tyrosine uptake into parasites.** The [¹³C] amino acid uptake data and oocyte experiments indicate a role for *TgApiAT5-3* in L-Tyr uptake into the parasite (Fig 4; Fig 5). To test the importance of *TgApiAT5-3* for L-Tyr uptake in *T. gondii*, we measured the kinetics of [¹⁴C]Tyr uptake in WT and Δ *apiAT5-3* parasites. The initial rate of [¹⁴C]Tyr uptake in Δ *apiAT5-3* parasites was decreased by 8.5-fold compared to that in WT parasites (Fig 7A; Fig S6A). Both [¹⁴C]Tyr uptake and parasite growth were increased upon complementation of the Δ *apiAT5-3* mutant with a constitutively expressed copy of *TgApiAT5-3* (*cTgApiAT5-3*/ Δ *apiAT5-3*; Fig 7A; Fig S7). However, uptake was not restored to WT levels, perhaps as a result of different levels of expression of *TgApiAT5-3* in the WT and complemented strains.

Our previous data indicated that *TgApiAT5-3* can transport other aromatic amino acids (Fig 6, Fig S5A). We measured uptake of [¹⁴C]Phe in WT and Δ *apiAT5-3* parasites. We found a significant, 2.5-fold decrease in the initial rate of [¹⁴C]Phe uptake in parasites lacking *TgApiAT5-3* (Fig. 7B; Fig S6B). We were unable to detect robust levels of uptake of [¹⁴C]Trp in either WT or Δ *apiAT5-3* parasites, precluding analysis of the role of *TgApiAT5-3* in uptake of this amino acid into parasites. As a control, we measured uptake of [¹⁴C]Arg, which is not transported by *TgApiAT5-3* (Fig 6; Fig S5A), in WT, Δ *apiAT5-3* and *cTgApiAT5-3*/ Δ *apiAT5-3* strain parasites. We found that the rate of [¹⁴C]Arg uptake did not

differ significantly between these parasite lines (Fig 7C; Fig S6C), indicating that the defect we observe in the uptake of aromatic amino acids is specific, and does not represent a general defect in amino acid uptake.

Growth of parasites lacking *TgApiAT5-3* is modulated by the concentrations of aromatic amino acids in the growth medium. We next investigated the dependence of the growth of $\Delta apiAT5-3$ parasites on the concentration of L-Tyr in the culture medium. WT and $\Delta apiAT5-3$ parasites were grown in DMEM containing 0 – 2.5 mM L-Tyr. Growth of WT parasites in the absence of L-Tyr was severely impaired (Fig S8A), consistent with a previous study that indicated *T. gondii* parasites are auxotrophic for this amino acid (20). WT parasites grew normally in [L-Tyr] as low as 10 μ M (Fig 8A). By comparison, growth of $\Delta apiAT5-3$ parasites was negligible at [L-Tyr] of 156 μ M and below, and severely impaired at concentrations below 1 mM (Fig 8A). We also measured growth of WT, $\Delta apiAT5-3$ and *cTgApiAT5-3*/ $\Delta apiAT5-3$ parasites grown in DMEM vs DMEM containing 2.5 mM L-Tyr, by plaque assay. Consistent with the results of the fluorescence growth assays, plaque assays revealed that impaired growth of $\Delta apiAT5-3$ parasites was restored by growth in 2.5 mM L-Tyr (Fig S7).

These data indicate that uptake of L-Tyr via *TgApiAT5-3* is important for the growth of *T. gondii* parasites in standard *in vitro* conditions. They also point to the existence of an alternative L-Tyr uptake pathway that can mediate sufficient L-Tyr uptake for parasite growth when parasites are cultured in medium containing ≥ 1 mM L-Tyr.

To assess the physiological significance of *TgApiAT5-3*-mediated L-Phe uptake for parasite growth, WT and $\Delta apiAT5-3$ were cultivated in medium containing 0 to 10 mM L-Phe (at a constant [L-Tyr] of 423 μ M, the concentration of this amino acid in DMEM). WT parasites

grew minimally in the absence of L-Phe (Fig S8B), indicating that *T. gondii* is auxotrophic for this amino acid, but grew normally at [L-Phe] of 39 μ M and above (Fig 8B). By contrast, growth of Δ apiAT5-3 parasites was impaired at 39 μ M [L-Phe] (Fig 8B). Δ apiAT5-3 parasites grew optimally at [L-Phe] between 78 μ M and 625 μ M, but parasite growth decreased at [L-Phe] of 1.25 mM and above (Fig 8B).

We next measured the growth of WT and Δ apiAT5-3 parasites in medium containing 0 – 1 mM L-Trp (and a constant [L-Tyr] of 423 μ M). WT parasites grew minimally in the absence of L-Trp (Fig S8C), consistent with a previous study that indicated *T. gondii* is auxotrophic for this amino acid (21). WT parasites grew optimally at 1 mM [L-Trp], and exhibited decreased growth with decreasing [L-Trp] (Fig 8C). By contrast, Δ apiAT5-3 parasites grew optimally at 16 – 125 μ M L-Trp (Fig 8C). Growth of Δ apiAT5-3 parasites was negligible at 4 μ M L-Trp (a concentration at which growth of WT parasites is only moderately impaired), and also decreased at [L-Trp] of 250 μ M and above (Fig 8C), mirroring the effects observed with growth of the mutant at a range of [L-Phe].

Together, these data reveal that *Tg*ApiAT5-3 is required for parasite growth at low exogenous concentrations of L-Phe and L-Trp, but not at intermediate concentrations. This points to the existence of other L-Phe and L-Trp uptake pathways in the parasite. Notably, *Tg*ApiAT5-3 is required for parasite growth at high exogenous L-Phe and L-Trp concentrations. This observation suggests that high concentrations of L-Phe or L-Trp may competitively inhibit uptake of L-Tyr via the alternative, non-*Tg*ApiAT5-3 L-Tyr uptake pathway (considered further in the Discussion).

***Tg*ApiAT5-3 is important for parasite virulence.** Standard media formulations used to culture parasite *in vitro* do not necessarily reflect the amino acid concentrations that parasites

encounter *in vivo*. Since the importance of *Tg*ApiAT5-3 for parasite growth *in vitro* is dependent on the concentrations of aromatic amino acids in the growth medium (Fig 8A-C), we investigated the importance of *Tg*ApiAT5-3 for parasite virulence in a mouse infection model. In preliminary experiments, we found that the parental TATi/Tomato WT parasite strain was avirulent in mice, precluding an analysis of whether Δ *apiAT5-3* parasites are virulent. We therefore remade the Δ *apiAT5-3* mutant in virulent RH Δ *hxgp*rt/Tomato strain parasites (22). Δ *apiAT5-3*/RH Δ *hxgp*rt/Tomato parasites were defective in uptake of [¹⁴C]Tyr (Fig S9A), and were dependent on high levels of exogenous L-Tyr for growth (Fig S9B). Notably, when we compared the growth of Δ *apiAT5-3*/RH Δ *hxgp*rt/Tomato parasites to parental RH Δ *hxgp*rt/Tomato parasites by plaque assay we found that, although growth in 2.5 mM Tyr partially restored growth of Δ *apiAT5-3*/RH Δ *hxgp*rt/Tomato strain parasites, this strain still grew slower than the parental parasites (Fig S9C). This is in contrast to the equivalent experiment with Δ *apiAT5-3*/TATi/Tomato parasites (Fig S7), and suggests some inter-strain differences in the importance of *Tg*ApiAT5-3 for *in vitro* growth, or in the availability of L-Tyr in the intracellular niche created by different strains.

We infected BALB/c mice intraperitoneally with 10³ WT (RH Δ *hxgp*rt/Tomato) or Δ *apiAT5-3*/RH Δ *hxgp*rt/Tomato parasites and monitored disease progression. Mice infected with WT parasites exhibited symptoms of toxoplasmosis and were euthanized 6 days post-infection (Fig 8D). In contrast, mice infected with Δ *apiAT5-3* parasites exhibited no symptoms of toxoplasmosis across the entire 62 days of the experiment (Fig 8D), indicating that *Tg*ApiAT5-3 is essential for parasite virulence.

Discussion

The evolution of apicomplexan ancestors from a free-living to an obligate parasitic life-style was associated with the loss of numerous biosynthetic pathways, including those for amino acid synthesis (23, 24). In particular, *T. gondii* is auxotrophic for many amino acids, including the aromatic amino acids L-Tyr, L-Phe and L-Trp ((5, 20, 21, 25-27); this study). Parasites must scavenge essential amino acids from their environment, although, in the case of apicomplexan parasites, how they do so is poorly understood. Here, we characterise a family of proteins predicted to function as transporters in apicomplexans. Using a combination of *in vitro*, *in vivo*, and heterologous expression studies, we provide evidence that these transporters localize to the parasite plasma membrane, and show that *TgApiAT5-3* functions as an aromatic amino acid transporter in *T. gondii*. We have previously demonstrated that other members of this family, which we now call *TgApiAT1* (previously *TgNPT1*) and *PbApiAT8-1* (previously *PbNPT1*), transport cationic amino acids (5). Our phylogenetic analyses indicate that ApiAT proteins are found throughout the apicomplexan phylum. To reflect these functions and phylogenetic affinities, we propose to rename this protein family the *Apicomplexan Amino acid Transporters* (ApiATs).

The ApiAT protein family is found in all apicomplexan species that we analyzed, as well as in chromerids, which are free-living relatives of apicomplexans. Chromerids are prototrophic for amino acids, although growth of these algae can be enhanced by the addition of glutamate and glycine to the growth medium, suggesting they can also acquire exogenous amino acids (28). Understanding the localization and function of chromerid ApiATs may provide valuable clues to the evolution of this transporter family in apicomplexans. The similarity of ApiATs to mammalian LAT3/4-type amino acid transporters suggests that the ancestral function of ApiATs was amino acid transport. The ApiATs appear to have undergone expansion in various apicomplexan lineages, including *Plasmodium* spp, *T. gondii* and piroplasms such as *Babesia* spp and *Theileria* spp, whereas only a single representative is present in

Cryptosporidium spp, an early-diverging lineage of apicomplexans (29). These observations are consistent with ancestral apicomplexans containing a single ApiAT protein that diversified in various lineages of the phylum to encompass new and/or more selective amino acid substrate selectivities.

A similar expansion has been observed in the amino acid/auxin permease (AAAP) family of trypanosomatid parasites, in which fourteen AAAP genes arose from a single AAAP gene locus through a series of gene duplication events in ancestral trypanosomatids (30). AAAP expansion is likely to reflect an early parasitic innovation that contributed to establishing parasite dependency on the host organism, and thereby facilitating the evolution of parasitism in trypanosomatids (23, 30). By contrast, much of the expansion in the ApiAT family appears to have occurred subsequent to the diversification of the major lineages in the phylum. Of the nine ApiAT subfamilies that we define, only the ApiAT2 subfamily is broadly distributed amongst the major apicomplexan lineages (Fig 1), suggesting its presence before these lineages diverged. Several subfamilies have undergone expansion within lineages. For example, the ApiAT3, 5, 6 and 7 subfamilies contain multiple members within coccidians (*T. gondii*, *N. caninum* and *E. tenella*), while piroplasms contain multiple ApiAT2 subfamily proteins (Fig 1).

Much of the expansion of ApiAT proteins, then, appears to have occurred subsequent to the evolution of parasitism in this phylum. An intriguing possibility is that expansion within ApiAT subfamilies is linked to expansion of these parasites into different hosts, and cell types within those hosts. Across their life cycles, apicomplexans such as *T. gondii*, *Plasmodium* spp and piroplasms must infect different hosts and/or different cell types with those hosts, which may necessitate amino acid transporters with different substrate affinities and specificities. Our data indicate that ten of the sixteen ApiAT family proteins in *T. gondii* are expressed in the tachyzoite stage of the life cycle (Fig 2; (5)). Of the ApiAT5 subfamily,

we could only detect expression of *TgApiAT5-3* in tachyzoites (Fig 2), and only *TgApiAT5-3* is important for growth of the tachyzoite stage (Fig 3). This raises the possibility that other *TgApiAT5* subfamily proteins are expressed, and function, at other stages of the life cycle. Interestingly, proteomic studies identified *TgApiAT5-5* in the oocyst proteome (www.toxodb.org), and it could be that this transporter has particular importance at this stage of the parasite life cycle.

Of the fifteen *ApiAT* family proteins that we were able to disrupt genetically, only the *TgApiAT1*, *TgApiAT2* and *TgApiAT5-3* mutants exhibited defects in tachyzoite growth (Fig 3). This corresponds to results from a recent genome-wide CRISPR-based screen, in which these three *TgApiAT* family proteins all had low ‘phenotype scores’ (scores between -3.91 and -4.73), an indicator of a gene’s importance for *in vitro* growth of tachyzoites ((31); scores below -1.8 are considered to be indicative of a gene being ‘important’ for parasite growth). The remaining *TgApiAT* family proteins had phenotype scores > -0.93 (31), consistent with the results of our targeted knockout approach which indicated that these proteins are not important for parasite growth *in vitro* (Fig 3). We were unable to disrupt the reading frame of *TgApiAT6-1*, despite multiple attempts using a guide RNA that targets the *TgApiAT6-1* locus (Table S1). *TgApiAT6-1* has a phenotype score of -5.4 (31). It is likely, then, that our inability to generate a *TgApiAT6-1* knockout is because it is essential for parasite growth.

Our studies of *TgApiAT5-3* demonstrate that this protein is important for parasite growth. We demonstrated that *TgApiAT5-3* is a high affinity L-Tyr uniporter (Fig 5; $K_{0.5} \sim 0.3 \mu\text{M}$, Table 1) and that loss of *TgApiAT5-3* leads to defects in L-Tyr uptake into parasites (Fig 4, Fig 7A). Furthermore, parasites lacking *TgApiAT5-3* were avirulent in mice (Fig 8D), and could only grow at extracellular L-Tyr concentrations above $\sim 1 \text{ mM}$ (Fig 8A), well above the plasma concentration of L-Tyr in mammals (estimated to be $55\text{-}90 \mu\text{M}$ in human plasma and

50-70 μ M in mouse plasma; (32, 33)). Together, our data point to an essential role for *TgApiAT5-3* in scavenging L-Tyr from the host.

Our oocyte studies indicated that *TgApiAT5-3* can function as an exchanger, with the rate of uptake of L-Tyr and other aromatic and large neutral amino acids enhanced when equivalent amino acids were present on the *trans* side of the membrane (Fig 6). Mammalian amino acid transporters function either as ‘loaders’ (i.e. uniporters that facilitate the uptake of amino acids into cells) or ‘harmonizers’ (i.e. exchangers that are essential for the maintenance of homeostatic amino acid concentrations) (34). By contrast, our data indicate that *TgApiAT5-3* performs an unusual dual function in facilitating both the net uptake of L-Tyr into the parasite, and maintaining intracellular pools of aromatic and large neutral amino acids through exchange. Maintaining amino acid homeostasis is critical for facilitating cellular metabolism and growth, and it is likely that *TgApiAT5-3* has a critical role in balancing the intracellular concentrations of aromatic and large neutral amino acids in the parasite.

X. laevis expression studies revealed that *TgApiAT5-3* transports L-Phe and L-Trp, as well as large neutral amino acids such as L-Leu (Fig 6). This raises the possibility that *TgApiAT5-3* also functions in the net uptake of these amino acids in the parasite. We saw no differences in the fractional labelling of [13 C]-labelled L-Leu or L-Ile in Δ *apiAT5-3* parasites compared to WT parasites (Fig 4), implying that the uptake of these branched-chain amino acids is facilitated by other transporters in the parasite. Similarly, we observed no defect in the fractional labelling of [13 C]-labelled L-Phe in parasites lacking *TgApiAT5-3* (Fig 4), although we did observe a defect in the uptake of [14 C]Phe in the mutant strain (Fig 7C). A possible explanation for this discrepancy lies in the different uptake conditions for these experiments. The [13 C]-labelled amino acid uptake experiments were performed in medium containing a complex mix of amino acids, whereas [14 C]Phe uptake was performed in medium containing L-Phe as the sole amino acid. Amino acids such as L-Tyr in the amino acid mix are likely to

compete with L-Phe for uptake by *Tg*ApiAT5-3 in WT parasites. Notably, uptake of [¹⁴C]Tyr into oocytes expressing *Tg*ApiAT5-3 was not impaired by the addition of equimolar amounts of unlabelled L-Phe (Fig S5A), indicating that *Tg*ApiAT5-3 has a greater affinity for L-Tyr than L-Phe. If a transporter's affinity for L-Tyr is much greater than that for L-Phe, uptake of the latter will be minimal in conditions where the amino acids are present at similar concentrations (as we observed in the oocyte experiments, and as appears to be the case in mammalian cells (32)). This is consistent with the hypothesis that *Tg*ApiAT5-3 plays little role in L-Phe uptake in the parasite. Instead, L-Phe is likely to be taken up via alternative transport pathways (Fig 9).

The importance of *Tg*ApiAT5-3 for L-Trp uptake in *T. gondii* is less clear. We were unable to detect the uptake of either [¹³C]Trp or [¹⁴C]Trp in parasites under different experimental conditions. In oocyte experiments, L-Trp can effectively out-compete L-Tyr for uptake via *Tg*ApiAT5-3 when present in equimolar amounts (Fig S5A), suggesting that *Tg*ApiAT5-3 has similar affinities for L-Trp and L-Tyr. We observed a defect in growth of Δ *apiAT5-3* parasites at low concentrations of L-Trp in the growth medium (below ~16 μ M; Fig 8C), suggesting that *Tg*ApiAT5-3 may have a role in the uptake of L-Trp at low concentrations. The estimated plasma concentration of L-Trp in humans and mice is ~60 μ M (33), a concentration at which Δ *apiAT5-3* parasites grow optimally *in vitro* (Fig 8C). However, *T. gondii* infection leads to an interferon γ (IFN γ) response in the host organism, which activates the L-Trp-degrading enzyme indoleamine 2,3-dioxygenase, leading to lowered serum levels of L-Trp and decreased parasite growth (21, 35). *Tg*ApiAT5-3 may, therefore, become important for L-Trp uptake following the IFN γ response upon parasite infection *in vivo* (Fig 9). Examining the importance of *Tg*ApiAT5-3 for L-Trp uptake upon IFN γ stimulation will be of particular interest for understanding the interplay between transporter function and the host response to parasite infection.

ΔapiAT5-3 parasites are capable of growth when the concentration of L-Tyr in the growth medium is ≥ 1 mM (Fig 8A). This indicates the existence of an alternative L-Tyr uptake pathway that takes up sufficient L-Tyr to enable parasite growth when L-Tyr levels are high (Fig 9). By contrast, *ΔapiAT5-3* parasites grew normally at intermediate concentrations of L-Phe (78 – 625 μ M) and L-Trp (31 – 250 μ M), but exhibited a dramatic decrease in growth at higher concentrations of both these amino acids (Fig 8B-C). These observations are consistent with the hypothesis that the alternative L-Tyr uptake pathway(s) also functions in L-Phe and L-Trp uptake (Fig 9). At high concentrations of L-Phe and L-Trp, uptake of L-Tyr by this alternative pathway(s) is inhibited by competition with the other aromatic amino acids, preventing parasite growth in the absence of *TgApiAT5-3*. This mirrors similar observations in our previous study on the alternative L-Arg uptake pathway in the parasite, in which we showed that high levels of other cationic amino acids inhibit parasite growth in the absence of the selective L-Arg transporter (5).

We propose a model whereby the uptake of L-Tyr into *T. gondii* parasites is mediated primarily by *TgApiAT5-3* (Fig 9). The uptake of L-Phe and L-Trp is mediated primarily by one or more alternative aromatic amino acid transporters. These transporters can also transport L-Tyr, and compensate for loss of *TgApiAT5-3* when L-Tyr levels are high and corresponding levels of L-Phe and L-Trp are lower (Fig 9). *TgApiAT5-3* has an additional role in facilitating homeostasis of these aromatic amino acids and large neutral amino acids (Fig 9).

This model is based on our observations of tachyzoite stage parasites. A recent study examined *T. gondii* aromatic amino acid hydroxylase enzymes, which can interconvert L-Phe and L-Tyr (36). Knockout of these enzymes revealed that they are not required for tachyzoite growth, but are particularly important for producing oocysts following the sexual stages of the parasite life cycle that occur in the felid hosts (36). Given the differences in aromatic

amino acid metabolism between tachyzoite and oocyst stages of the life cycle, it is likely that the nature and requirements for aromatic amino acid transporters differs across the life cycle of the parasite. Future studies that investigate the expression and importance of *TgApiAT5-3* and other aromatic amino acid transporters (perhaps other members of the *TgApiAT5* family) across the entire life cycle will be of particular interest.

In this manuscript, we describe an apicomplexan-specific family of plasma membrane transporters that appear to be primarily involved in amino acid uptake. Our findings highlight the evolutionary novelties that must arise to enable parasites to scavenge essential nutrients from their hosts, and also highlight the importance of amino acid scavenging for the growth and virulence of the disease-causing tachyzoite stage *T. gondii*. Future studies that examine the role of other members of this transporter family across the entire life cycle of the parasite will facilitate a better understanding of how these parasites acquire amino acids from their hosts.

Materials and Methods

Phylogenetic analysis of the ApiAT protein family

Reciprocal protein BLAST searches in www.eupathdb.org were used to identify orthologues of the five previously identified *Plasmodium falciparum* ApiAT genes in the genomes of the apicomplexans *Plasmodium berghei*, *Toxoplasma gondii*, *Cryptosporidium parvum*, *Eimeria tenella*, *Neospora caninum*, *Babesia bovis* and *Theileria annulata*, and the chromerids *Chromera velia* and *Vitrella brassicaformis*. Gene IDs are listed in Table S3.

The sequences of the 67 identified ApiAT proteins were aligned using ClustalX 2.1. The multiple sequence alignment was edited in Jalview (www.jalview.org) to remove poorly aligned blocks. After sequence editing, 452 residues were left for subsequent phylogenetic

analysis using PHYLIP v3.69 (evolution.genetics.washington.edu/phylip/getme.html) as described previously (37). Briefly, a consensus maximum likelihood tree and bootstrap values were generated by running the alignment file through the ‘seqboot’ program, which was used to generate 1000 pseudosamples of the alignment. Next, multiple phylogenetic trees were generated from the pseudosamples using the ‘proml’ tree algorithm, using a randomised order of entry and three jumbles. Finally, the multiple phylogenetic trees were converted to a consensus tree with bootstrap values using the program ‘consense’. Trees were viewed using the program FigTree (<http://tree.bio.ed.ac.uk/software/figtree/>) and annotated using Inkscape (<https://inkscape.org/en>). For visual representation of the alignment, shading for sequence identity was carried out using the TexShade package for LaTeX, using similarity mode with the ‘fingerprint’ command (<https://ctan.org/pkg/texshade?lang=en>).

Parasite culture

Parasites were maintained in human foreskin fibroblasts (HFFs; a kind gift from Holger Schülter, Peter MacCallum Cancer Centre) cultured at 37°C in a humidified 5 % CO₂ incubator. Unless otherwise noted, parasites were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1 % (v/v) fetal calf serum and antibiotics. ‘Homemade’ media were generated as described previously (5), with amino acids at the concentrations found in DMEM, or modified as specified in the text. Δ *apiAT5-3* parasites were grown continuously in DMEM supplemented with 2.5 mM L-Tyr. TATi (38), TATi/Tomato, TATi/ Δ *ku80* (39), and RH Δ *hxgprt*/Tomato (22) parasites were used as parental strains for the genetically modified parasites generated in this study.

Generation of genetically modified *T. gondii* parasites

581 Guide RNA (gRNA)-encoding sequences specific to target genes were introduced into the
582 vector pSAG1::Cas9-U6::sgUPRT (Addgene plasmid # 54467; (18)) using Q5 site-directed
583 mutagenesis (New England Biolabs) as described previously (18). A list of the forward
584 primers used to generate gRNA-expressing vectors for introducing frame-shift mutations are
585 described in Table S4. In each instance, the reverse primer 5'-
586 AACTTGACATCCCCATTTAC was used. For generating 'knockout' frameshift mutations
587 in *TgApiAT* genes, gRNAs were designed to target the open reading frames of *TgApiAT*
588 genes, and transfected into parasites on a vector that also expressed Cas9-GFP. Transfections
589 were performed as described previously (40). GFP positive parasites were selected and
590 cloned using flow cytometry 2-3 days following transfection using a FACS Aria I or
591 FACS Aria II cell sorter (BD Biosciences). The region of the candidate genes targeted by the
592 gRNAs were sequenced in clonal parasites, and clones in which the target gene had been
593 disrupted by a frameshift mutation or insertion of a premature stop codon (i.e. where the open
594 reading frame was disrupted) were selected for subsequent analyses. For 3' replacements,
595 gRNAs were selected to target a region near the stop codon of the gene of interest, using the
596 primers listed in Table S5. In addition, a donor DNA sequence encoding a 3x HA tag was
597 amplified by PCR to contain 50 bp of flanking sequences homologous to the target gene
598 either side of the stop codon. Template DNA encoding the 3x HA tag was generated as a
599 gBlock (Integrated DNA Technologies), with the sequence listed in Table S6. Forward and
600 reverse primers used to amplify the HA tag for each target gene are also listed in Table S6.
601 gRNA-expressing vectors, which simultaneously encode Cas9 fused to GFP, were co-
602 transfected into *T. gondii* parasites with the donor DNA sequence. 2-3 days after transfection,
603 GFP-Cas9-expressing parasites were selected and cloned into wells of a 96-well plate by flow
604 cytometry as described above.

3' replacement plasmids were created to epitope tag *TgApiAT2*, *TgApiAT3-2*, *TgApiAT3-3*, *TgApiAT5-3*, *TgApiAT6-1*, *TgApiAT6-2* and *TgApiAT7-1* using conventional crossover recombination methods as described previously (41). Regions of DNA homologous to the 3' ends of the genes were amplified by PCR using primers described in Table S7, and ligated into the *Bgl*II and *Avr*II sites of the vector pgCH (5) or the *Pac*I and *Avr*II sites of pLIC-HA₃-DHFR (41). Resulting plasmids were linearized in the flanking sequence using restriction enzymes (Table S7), then transfected into TATi/ Δ *ku80* parasites. Parasites were selected on chloramphenicol or pyrimethamine as described (40). In cases where we were unable to subsequently detect protein of approximately the expected molecular mass by western blotting, we confirmed correct integration of the HA tag by sequencing of CRISPR-modified 3' ends (*TgApiATs* 5-1, 5-2, 5-4, 5-5 and 5-6; not shown), or by PCR screening (*TgApiAT7-1*). For assessing HA integration into the *TgApiAT7-1* locus, DNA was extracted from *TgApiAT7-1*-HA parasite clones, and used as template in a PCR with the primers 5'-GGCGAAGAGAAGGCGTTG and 5'-GTCATCCCTTTTCTTCGATAA, with the presence of a 2.5 kb band indicative of successful integration (Fig S3C).

To complement the Δ *apiAT2* mutant with a constitutively-expressed copy of *TgApiAT2*, we amplified the open reading frame of *TgApiAT2* from genomic DNA with the primers 5'-GATCGGATCCAAAATGGCGGCTGCTCAG and 5'-GATCCCTAGGCACAGCGACCTCTGGACTCGGT. We digested the resultant PCR product with *Bam*HI and *Avr*II and ligated this into the *Bgl*II and *Avr*II sites of the pUgCTH₃ vector (5). The resultant vector was linearised with *Mfe*I, transfected into Δ *apiAT2* parasites and selected on chloramphenicol. To complement the Δ *apiAT5-3* mutant with a constitutively-expressed copy of *TgApiAT5-3*, we amplified the open reading frame of *TgApiAT5-3* with the primers 5'-GATCGGATCCAAAATGGAGTCGACCGAGGCGACTAT and 5'-

GATCCCTAGGCAGCACCTTCGGGACTTTTCTCTTC, using the *Tg*ApiAT5-3-
expressing oocyte vector (described below) as template. We digested the resultant PCR
product with *Bam*HI and *Avr*II and ligated this into the *Bgl*II and *Avr*II sites of the pUgCTH₃
vector. The resultant vector was linearised with *Mfe*I, transfected into Δ *apiAT5-3* parasites
and selected on chloramphenicol.

Immunofluorescence assays and western blotting

Immunofluorescence assays and western blotting were performed as described previously (5).
For western blotting, membranes were probed with rat anti-HA antibodies (clone 3F10,
Sigma) at dilutions between 1:1,000 to 1:3,000, mouse anti-GRA8 (a kind gift from Gary
Ward, U. Vermont, (42)) at a dilution of 1:80,000, or rabbit anti-*Tg*Tom40 antibodies (43) at
1:2,000 dilution, and horseradish peroxidase (HRP)-conjugated goat anti-rat (sc-2006, Santa
Cruz Biotechnology), HRP-conjugated goat anti-mouse (sc-2005, Santa Cruz
Biotechnology), or HRP-conjugated goat anti-rabbit (sc-2004, Santa Cruz Biotechnology)
antibodies at dilutions of 1:5,000 to 1:10,000.

For immunofluorescence assays, samples were probed with the following primary antibodies:
rat anti-HA (clone 3F10, Sigma) at a 1:200 dilution, mouse anti-P30 (clone TP3, Abcam) at a
1:2,000 dilution, rabbit anti-P30 (a kind gift from John Boothroyd, Stanford U) at dilutions
between 1:25,000 and 1:90,000, or rabbit anti-GFP (a kind gift from Alex Maier, ANU) at a
1:200 dilution. Samples were next probed with the following secondary antibodies: CF488A-
conjugated goat anti-rat (SAB4600046, Sigma) at a dilution of 1:500, AlexaFluor 488-
conjugated goat anti-rat (4416, Cell Signaling Technology) at dilution of 1:250,
AlexaFluor488-conjugated goat anti-rabbit (A11008, Life Technologies) at a dilution of 1:500,
AlexaFluor546-conjugated goat anti-rabbit (A11035, Life Technologies) at a dilution of 1:500,

AlexFluor546-conjugated goat anti-mouse (A11030, Life Technologies) at a dilution of 1:500, or AlexFluor647-conjugated goat anti-mouse (A21236, Life Technologies) at a dilution of 1:500.

Fluorescence microscopy was performed on a DeltaVision Elite system (GE Healthcare) using an Olympus IX71 inverted microscope with a 100X UPlanSApo objective lens (NA 1.40). Images were recorded using a CoolSNAP HQ2 camera. Images were deconvolved using SoftWoRx Suite 2.0 software, and images were linearly adjusted for contrast and brightness.

Parasite growth and virulence assays

To measure parasite growth by plaque assays, either 150 parasites were added to wells of a 6-well plate containing confluent HFFs, or 500-1,000 parasites were added to confluent HFFs in 25 cm² tissue culture flasks. Parasites were allowed to grow for 8 to 18 days before fixation and staining with crystal violet as described previously (40).

Fluorescence growth assays were performed as described previously (44, 45), with slight modifications. Briefly, wells of an optical bottom 96-well plate containing confluent HFFs were washed twice in medium lacking L-Tyr, L-Phe or L-Trp. Wells were filled with medium containing a range of L-Tyr, L-Phe or L-Trp concentrations. 2,000 parasites were inoculated into each of these wells, and plates were incubated at 37°C in a 5% CO₂ incubator. Well fluorescence was measured 5 days post-inoculation in a FluoStar Optima fluorescence plate reader (BMG Labtech), a time point at which WT parasites were in mid-logarithmic stage of growth. Relative growth was expressed as a percentage of the well fluorescence in the optimum amino acid concentration for WT or Δ *apiAT5-3* parasites at this time point.

To measure parasite virulence, freshly egressed WT (RH Δ hxgprt/Tomato) or Δ apiAT5-3 in RH/ Δ hxgprt/Tomato parasites were filtered through a 3 μ m polycarbonate filter, washed once in phosphate-buffered saline (PBS), then were diluted to 10⁴ parasites/ml in PBS. 10³ parasites were injected intraperitoneally into 7-week-old, female Balb/c mice using a 26-gauge needle. Mice were weighed regularly, and monitored for symptoms of toxoplasmosis (weight loss, ruffled fur, lethargy and hunched posture). Mice exhibiting terminal symptoms of toxoplasmosis were euthanized in accordance with protocols approved by the Australian National University Animal Experimentation Ethics Committee (protocol number A2016/42).

[¹³C]Amino acid labelling and detection.

Freshly egressed WT or Δ apiAT5-3 tachyzoites (10⁸) were incubated in 500 μ L of amino acid-free Roswell Park Memorial Institute 1640 medium supplemented with 2 mg/ml algal [¹³C]amino acid mix (Cambridge Isotope Laboratories) for 15 minutes at 37°C in a 5% CO₂ incubator. [¹³C]amino acid labelling was terminated by rapid dilution in 14 ml of ice cold PBS. Parasite metabolites were extracted in chloroform:methanol:water (1:3:1 v/v/v) containing 1 nmol *scyllo*-inositol (Sigma). The aqueous phase metabolites were dried in a heated speedvac concentrator, methoxymated by treatment with 20 mg/ml methoxyamine in pyridine overnight, then trimethylsilylated by treatment with N,O-bis(trimethylsilyl)trifluoroacetamide containing 1% trimethylsilyl for 1 hr at room temperature. Samples were analyzed using GC-MS as described previously (46). The fractional labelling of all detected amino acids was estimated as the fraction of the metabolite pool containing one or more ¹³C-atoms after correction for natural abundance. Total metabolite counts were normalized to *scyllo*-inositol as an internal standard.

***Xenopus laevis* oocyte preparation and *TgApiAT5-3* expression.**

The open reading frame of *TgApiAT5-3* was amplified from RH Δ *hxgprt* strain cDNA template using the primers 5'-GATCACCGGTCCACCATGGAGTCGACCGAGGCGACTAT and 5'-GATCCCTAGGCAGCACCTTCGGGACTTTTCTCTTC. The resultant product was digested with *Age*I and *Avr*II, and ligated into the *Xma*I and *Avr*II sites of the vector pGHJ-HA (5). The plasmid was linearised by incubation in *Not*I overnight, and complementary RNA (cRNA) encoding HA-tagged *TgApiAT5-3* was prepared for injection into oocytes as previously described (47-49). *Xenopus laevis* oocytes were surgically removed and prepared for cRNA injection as described (48). For all transporter assays in oocytes, 15 ng of *TgApiAT5-3* cRNA was micro-injected into stage 5 or 6 oocytes using a Micro4TM micro-syringe pump controller and A203XVY nanoliter injector (World Precision Instruments). Maintenance of animals and preparation of oocytes was approved by the Australian National University Animal Experimentation Ethics Committee (protocol number A2014/20).

Oocyte surface biotinylation and whole membrane preparation.

Oocyte surface biotinylation and whole membrane preparations were performed as described previously (48, 50). Briefly, for surface biotinylation, 15 oocytes were selected 3-6 days post cRNA injection, washed thrice in ice-cold PBS (pH 8.0), incubated for 45 mins at room temperature in 0.5 mg/ml of EZ-LinkTM Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific), and then washed thrice more in ice-cold PBS. Oocytes were subsequently solubilised in oocyte lysis buffer (20 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% v/v Triton X-100) for 2 hr on ice. Samples were centrifuged at 16,000 *g*, and the supernatant was mixed with 50 μ l of streptavidin-coated agarose beads (Thermo Fisher Scientific). The mixture was incubated at 4°C on slow rotation overnight. Beads were washed 4 times with oocyte lysis buffer before

elution in SDS-PAGE sample buffer. For whole membrane preparation, 10-25 oocytes were homogenised by trituration in homogenisation buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1 mM EDTA, protease inhibitors). Homogenised oocytes were centrifuged at 2,000 *g* for 10 min at 4 °C and the resulting supernatant further centrifuged for 30 min at 140,000 *g* at 4°C. The resulting pellet was washed with homogenisation buffer and solubilised in homogenisation buffer containing 4 % (w/v) SDS, and then in SDS-PAGE sample buffer. Protein samples from surface biotinylation and whole membrane preparations were separated by SDS-PAGE then detected by western blotting as described above.

Oocyte uptake, efflux and electrophysiology

For uptake experiments in either non-preloaded, preloaded, or pre-injected oocytes, batches of 10 oocytes were washed 4 times in ND96 buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl₂, 1.8 mM CaCl₂, 5 mM HEPES, pH 7.4) at RT, and then incubated in the desired concentration of radiolabelled substrates as indicated in figure legends. For all substrate screening measurements, uptake was measured over 10 mins. For kinetic experiments, parallel batches of oocytes were preloaded with 0 – 1.78 mM L-Tyr, and uptake of [¹⁴C]Tyr at a range of L-Tyr concentrations was measured over 10 mins. For other uptake experiments, uptake was measured for the time-course indicated in the figures. Uptake was quenched by washing oocyte batches four times in ice-cold ND96.

For efflux experiments, batches of 5 oocytes/substrate were preloaded with [¹⁴C]L-amino acids as described below. Following preloading, oocytes were washed 4 times in ND96 and incubated in trans-stimulating substrates at concentrations described in the figure legends. To measure the amount of efflux, oocytes were incubated in 500 µl aliquots of the extracellular solution, of which 100 µl was removed for each time point and the efflux immediately quenched by washing oocytes in four times in ice-cold ND96. Oocyte retention was

measured by removing the oocytes following quenching of efflux. For the substrate efflux screen depicted in Fig 6B, the extracellular solution was sampled at 5 min to ensure initial rate measurements. For efflux experiments depicted in Fig 5C, efflux was measured for the time-course indicated in the figure.

Following all uptake and efflux experiments, oocytes or aliquots were distributed into OptiPlate96-well plates (Perkin-Elmer) and oocytes were lysed overnight in 10 % (w/v) SDS. 150 μ l/well of Microscint-40 scintillation fluid (Perkin-Elmer) was added to the samples, and plates covered and shaken for 5 min before radioactivity was counted on a Perkin-Elmer MicroBeta² 2450 microplate scintillation counter.

All steady-state electrical recordings were made with an Axon GeneClamp 500B amplifier (Axon Instruments) in a two-voltage clamp configuration as previously described (50, 51). Voltage clamp was set to -50 mV or 0 mV and data were sampled at 3 Hz using pClamp 8.2 software (Axon Instruments). Boron silicate microelectrodes capillaries (World Precision Instruments) with a tip resistance of: $1.5 \geq R_e \geq 0.5$ M Ω were pulled by a P-97 Flaming/Brown micropipette puller (Sutter Instruments) and filled with 3 M KCl. Silver microelectrodes were coated using a 5 M NaCl single-chamber galvanic cell to form AgCl₂ electrodes. The membrane potential was adjusted digitally in voltage-clamp mode between 0 and -50 mV. Oocytes were chosen for recording when they had a resting membrane potential -25 mV $< E_m < -45$ mV. ND96 (pH 7.4) was used as the control solution for all electrophysiological recordings. Assay buffer pH was varied by mixing different ratios of acidic ND96 (pH 3.6) (5 mM MES instead of HEPES) with basic ND96 (pH 10) (5 mM Tris instead of HEPES).

Oocyte preloading and pre-injection of trans-substrates.

For uptake experiments measuring *trans*-stimulation by a range of amino acids and other metabolites (Fig 6A and Fig S5B), all L-amino acids substrates and metabolite mixes, except for L-Tyr, were pre-injected at 25 nl/oocyte using a Micro4TM micro-syringe pump controller and A203XVY nanoliter injector (World Precision Instruments). All pre-injected oocytes were incubated on ice for 30 mins prior to uptake experiments. Stock solutions containing 100 mM L-amino acids in ND96 were pre-injected to give a calculated cytosolic concentration of 5 mM, based on an assumed free aqueous volume of 500 nl/oocyte. Stage 5 or 6 oocytes diameters vary significantly from 1–1.3 mm and free aqueous oocyte volumes measured from 368 to > 500 nl (52, 53). Therefore, calculations of cytosolic concentrations from pre-injection should be treated as approximations only. In Fig. S5B, pre-injection of different metabolite groups was conducted to give estimated final concentrations of each metabolite as indicated in Table S2. The low solubility of L-Tyr in aqueous solutions (0.453 g/L at 25°C, pH 7.4; (54)) necessitated preloading, rather than pre-injecting, substrate for *trans*-stimulation and efflux substrate specificity experiments. L-Tyr solutions were made by dissolving 2.5 mM L-Tyr in ND96 at 37°C and performing dilutions in ND96 to the required concentrations. Pre-loading of L-tyrosine in *TgApiAT5-3*-injected oocytes was tested by timing the pre-loading of 2.5 or 1 mM [¹⁴C]Tyr (data not shown). L-tyrosine equilibrium was reached after 10 to 12 hr, while uninjected oocytes reached a similar cytosolic concentration after incubation of approximately 68-72 hr. As a consequence, L-Tyr was preloaded for 32 hr in *TgApiAT5-3* injected oocytes and for 72 hr in uninjected oocytes for all *trans*-stimulation experiments. Greater than 90% of [¹⁴C]Tyr was effluxed from oocytes preloaded with 2.5 mM labelled L-Tyr, indicating L-Tyr is not significantly metabolised during the preloading times used in experiments (data not shown).

All efflux substrate screening with [¹⁴C]labelled amino acids (Fig 6B) were conducted by preloading [¹⁴C]labelled L-amino acids for 3 hr prior to uptake. [¹⁴C]Tyr was preloaded at a

concentration of 2.5 mM, while the other [^{14}C]labelled L-amino acids were preloaded at a concentration of 5 mM. Calculation of the pre-loaded [^{14}C]labelled L-amino acids concentrations were conducted using a control set of oocytes for each substrate, pre-loaded in parallel to those used for efflux *trans*-stimulation. Calculations were made assuming a cytosolic volume of 500 nl/oocyte.

Oocyte data analysis and statistics.

All oocyte data were analyzed using OriginPro (2015). All data displayed in figures represent the mean $\pm$ S.D. except where otherwise indicated. Unless uptake data from uninjected oocytes is included in figures, uptake in uninjected oocytes was subtracted from uptake in *TgApiAT5-3*-injected oocytes to give the '*TgApiAT5-3*-mediated uptake'. All data sets were analysed for Gaussian normalcy by first running a Shapiro-Wilk test prior to analysis and used only if passing the normalcy test at the $P < 0.05$ level. Multi-variant experiments with 3 or more experimental conditions were subjected to a one-way ANOVA with Dunnet's post-hoc test and significance tested at the $P < 0.05$ level.

Time-course analysis of uptake and oocyte retention data of L-Tyr in *TgApiAT5-3*-injected oocytes were fitted to 1st order integrated rate equations:

$$S_t = S_0 e^{-kt} \quad (\text{eq. 1, retention})$$

Or:

$$S_t = S_{\max} (1 - e^{-kt}) \quad (\text{eq. 2, uptake})$$

Equation 2 being the Box Lucas 1 model with zero offset (55), where S_t , and S_0 , and are the amount of substrate (S) at variable time (t), or when $t = 0$, $S_{\max}$ is the vertical asymptote of substrate amount, and k is the 1st order rate constant.

Steady-state kinetic data collected under initial rate conditions were fitted to both the Michaelis-Menten equation:

$$v = \frac{V_{max} \cdot [S]}{K_{0.5} + [S]} \quad (\text{eq. 3})$$

And a Scatchard linear regression equation:

$$\frac{v}{[S]} = \frac{V_{max}}{K_{0.5}} - \frac{v}{K_{0.5}} \quad (\text{eq. 4})$$

In the Scatchard regression, the apparent Michaelis constant ($K_{0.5}$) is derived from the slope ($1/K_{0.5}$) and the maximal rate (V_{max}) from the ordinate intercept ($V_{max}/K_{0.5}$).

All curve fittings were evaluated using adjusted R^2 values as indicated in the text and figure legends. All non-linear fitting was conducted using the Levenburg-Marquardt algorithm, with iteration numbers varying from 4 to 11 before convergence was attained.

***T. gondii* amino acid assays**

Amino acid uptake assays were carried out as described previously (5), with slight modifications. Briefly, extracellular parasites were washed twice in Dulbecco's PBS pH 7.4 (Sigma) supplemented with 10 mM glucose (PBS-glucose). Parasites were incubated in PBS-glucose containing radiolabelled amino acids, and 200 μ l aliquots removed at regular time points. Parasite samples were centrifuged through an oil mix to separate parasites from unincorporated radiolabel as described previously (5). L-Arg uptake was measured by incubation in 0.1 μ Ci/mL [14 C]Arg and 100 μ M L-Arg, L-Tyr uptake was measured by incubation in 0.25 μ Ci/mL [14 C]Tyr and 60 μ M L-Tyr, and L-Phe uptake was measured by incubation in 0.1 μ Ci/mL [14 C]Phe and 15 μ M L-Phe. The time courses of radiolabel uptake

845 in each amino acid tested were fitted by a single exponential function and the initial rate of
846 transport was estimated from the initial slope of the fitted line.

847

848 **Acknowledgements**

849 We are grateful to students from the 2016 Biology of Parasitism course (Woods Hole, MA)
850 for performing some of the early studies to characterise the role of *Tg*ApiAT5-3 in aromatic
851 amino acid transport. We thank Harpreet Vohra and Michael Devoy for performing flow
852 cytometry.

References

1. Striemen B. Parasitic infections: Time to tackle cryptosporidiosis. *Nature*. 2013;503(7475):189-91.
2. Montoya JG, Liesenfeld O. Toxoplasmosis. *Lancet*. 2004;363(9425):1965-76.
3. Kirk K, Lehane AM. Membrane transport in the malaria parasite and its host erythrocyte. *Biochem J*. 2014;457(1):1-18.
4. Kenthirapalan S, Waters AP, Matuschewski K, Kooij TW. Functional profiles of orphan membrane transporters in the life cycle of the malaria parasite. *Nat Commun*. 2016;7:10519.
5. Rajendran E, Hapuarachchi SV, Miller CM, Fairweather SJ, Cai Y, Smith NC, et al. Cationic amino acid transporters play key roles in the survival and transmission of apicomplexan parasites. *Nat Commun*. 2017;8:14455.
6. Martin RE, Henry RI, Abbey JL, Clements JD, Kirk K. The 'permeome' of the malaria parasite: an overview of the membrane transport proteins of *Plasmodium falciparum*. *Genome Biol*. 2005;6(3):R26.
7. Boisson B, Lacroix C, Bischoff E, Gueirard P, Bargieri DY, Franke-Fayard B, et al. The novel putative transporter NPT1 plays a critical role in early stages of *Plasmodium berghei* sexual development. *Mol Microbiol*. 2011;81(5):1343-57.
8. Behnke MS, Khan A, Sibley LD. Genetic mapping reveals that sinefungin resistance in *Toxoplasma gondii* is controlled by a putative amino acid transporter locus that can be used as a negative selectable marker. *Eukaryot Cell*. 2015;14(2):140-8.
9. Aurecochea C, Barreto A, Brestelli J, Brunk BP, Cade S, Doherty R, et al. EuPathDB: the eukaryotic pathogen database. *Nucleic Acids Res*. 2013;41(Database issue):D684-91.
10. Moore RB, Obornik M, Janouskovec J, Chrudimsky T, Vancova M, Green DH, et al. A photosynthetic alveolate closely related to apicomplexan parasites. *Nature*. 2008;451(7181):959-63.
11. Coordinators NR. Database Resources of the National Center for Biotechnology Information. *Nucleic Acids Res*. 2017;45(D1):D12-D7.
12. Finn RD, Clements J, Eddy SR. HMMER web server: interactive sequence similarity searching. *Nucleic Acids Res*. 2011;39(Web Server issue):W29-37.
13. Bodoy S, Fotiadis D, Stoeger C, Kanai Y, Palacin M. The small SLC43 family: facilitator system I amino acid transporters and the orphan EEG1. *Mol Aspects Med*. 2013;34(2-3):638-45.
14. Pao SS, Paulsen IT, Saier MH, Jr. Major facilitator superfamily. *Microbiol Mol Biol Rev*. 1998;62(1):1-34.
15. Reddy VS, Shlykov MA, Castillo R, Sun EI, Saier MH, Jr. The major facilitator superfamily (MFS) revisited. *FEBS J*. 2012;279(11):2022-35.
16. Sonnhammer EL, von Heijne G, Krogh A. A hidden Markov model for predicting transmembrane helices in protein sequences. *Proc Int Conf Intell Syst Mol Biol*. 1998;6:175-82.
17. Sangare LO, Alayi TD, Westermann B, Hovasse A, Sindikubwabo F, Callebaut I, et al. Unconventional endosome-like compartment and retromer complex in *Toxoplasma gondii* govern parasite integrity and host infection. *Nat Commun*. 2016;7:11191.
18. Shen B, Brown KM, Lee TD, Sibley LD. Efficient gene disruption in diverse strains of *Toxoplasma gondii* using CRISPR/CAS9. *MBio*. 2014;5(3):e01114-14.
19. Stein WDaL, W.R. Facilitated Diffusion: The Simple Carrier. *Transport and Diffusion across Cell Membranes*. Orlando, FLA, U.S.A.: ACADEMIC PRESS; 1986. p. 231-361.
20. Marino ND, Boothroyd JC. *Toxoplasma* growth in vitro is dependent on exogenous tyrosine and is independent of AAH2 even in tyrosine-limiting conditions. *Exp Parasitol*. 2017;176:52-8.
21. Pfefferkorn ER. Interferon gamma blocks the growth of *Toxoplasma gondii* in human fibroblasts by inducing the host cells to degrade tryptophan. *Proc Natl Acad Sci U S A*. 1984;81(3):908-12.
22. Chtanova T, Schaeffer M, Han SJ, van Dooren GG, Nollmann M, Herzmark P, et al. Dynamics of neutrophil migration in lymph nodes during infection. *Immunity*. 2008;29(3):487-96.

- 903 23. Janouskovec J, Keeling PJ. Evolution: Causality and the Origin of Parasitism. *Curr Biol*.
904 2016;26(4):R174-7.
- 905 24. van Dooren GG, Striepen B. The algal past and parasite present of the apicoplast. *Annu Rev*
906 *Microbiol*. 2013;67:271-89.
- 907 25. Coppens I. Exploitation of auxotrophies and metabolic defects in *Toxoplasma* as therapeutic
908 approaches. *Int J Parasitol*. 2014;44(2):109-20.
- 909 26. Sibley LD, Messina M, Niesman IR. Stable DNA transformation in the obligate intracellular
910 parasite *Toxoplasma gondii* by complementation of tryptophan auxotrophy. *Proc Natl Acad Sci U S A*.
911 1994;91(12):5508-12.
- 912 27. Tymoshenko S, Oppenheim RD, Agren R, Nielsen J, Soldati-Favre D, Hatzimanikatis V.
913 Metabolic needs and capabilities of *Toxoplasma gondii* through combined computational and
914 experimental analysis. *PLoS Comput Biol*. 2015;11(5):e1004261.
- 915 28. Foster C, Portman N, Chen M, Slapeta J. Increased growth and pigment content of *Chromera*
916 *velia* in mixotrophic culture. *FEMS Microbiol Ecol*. 2014;88(1):121-8.
- 917 29. Kuo CH, Wares JP, Kissinger JC. The Apicomplexan whole-genome phylogeny: an analysis of
918 incongruence among gene trees. *Mol Biol Evol*. 2008;25(12):2689-98.
- 919 30. Jackson AP, Otto TD, Aslett M, Armstrong SD, Bringaud F, Schlacht A, et al. Kinetoplastid
920 Phylogenomics Reveals the Evolutionary Innovations Associated with the Origins of Parasitism. *Curr*
921 *Biol*. 2016;26(2):161-72.
- 922 31. Sidik SM, Huet D, Ganesan SM, Huynh MH, Wang T, Nasamu AS, et al. A Genome-wide
923 CRISPR Screen in *Toxoplasma* Identifies Essential Apicomplexan Genes. *Cell*. 2016;166(6):1423-35.
- 924 32. Bergstrom J, Furst P, Noree LO, Vinnars E. Intracellular free amino acid concentration in
925 human muscle tissue. *J Appl Physiol*. 1974;36(6):693-7.
- 926 33. Cantor JR, Abu-Remaileh M, Kanarek N, Freinkman E, Gao X, Louissaint A, Jr., et al.
927 Physiologic Medium Rewires Cellular Metabolism and Reveals Uric Acid as an Endogenous Inhibitor
928 of UMP Synthase. *Cell*. 2017;169(2):258-72 e17.
- 929 34. Broer S, Broer A. Amino acid homeostasis and signalling in mammalian cells and organisms.
930 *Biochem J*. 2017;474(12):1935-63.
- 931 35. Engin AB, Dogruman-Al F, Ercin U, Celebi B, Babur C, Bukan N. Oxidative stress and
932 tryptophan degradation pattern of acute *Toxoplasma gondii* infection in mice. *Parasitol Res*.
933 2012;111(4):1725-30.
- 934 36. Wang ZT, Verma SK, Dubey JP, Sibley LD. The aromatic amino acid hydroxylase genes AAH1
935 and AAH2 in *Toxoplasma gondii* contribute to transmission in the cat. *PLoS Pathog*.
936 2017;13(3):e1006272.
- 937 37. Foth BJ. Phylogenetic analysis to uncover organellar origins of nuclear-encoded genes.
938 *Methods Mol Biol*. 2007;390:467-88.
- 939 38. Meissner M, Schluter D, Soldati D. Role of *Toxoplasma gondii* myosin A in powering parasite
940 gliding and host cell invasion. *Science*. 2002;298(5594):837-40.
- 941 39. Sheiner L, Demerly JL, Poulsen N, Beatty WL, Lucas O, Behnke MS, et al. A systematic screen
942 to discover and analyze apicoplast proteins identifies a conserved and essential protein import
943 factor. *PLoS Pathog*. 2011;7(12):e1002392.
- 944 40. Striepen B, Soldati D. Genetic manipulation of *Toxoplasma gondii*. In: Weiss LD, Kim K,
945 editors. *Toxoplasma gondii* The Model Apicomplexan - Perspectives and Methods. London: Elsevier;
946 2007. p. 391-415.
- 947 41. Huynh MH, Carruthers VB. Tagging of endogenous genes in a *Toxoplasma gondii* strain
948 lacking Ku80. *Eukaryot Cell*. 2009;8(4):530-9.
- 949 42. Carey KL, Donahue CG, Ward GE. Identification and molecular characterization of GRA8, a
950 novel, proline-rich, dense granule protein of *Toxoplasma gondii*. *Mol Biochem Parasitol*.
951 2000;105(1):25-37.
- 952 43. van Dooren GG, Yeoh LM, Striepen B, McFadden GI. The Import of Proteins into the
953 Mitochondrion of *Toxoplasma gondii*. *J Biol Chem*. 2016;291(37):19335-50.

44. Gubbels MJ, Li C, Striepen B. High-throughput growth assay for *Toxoplasma gondii* using yellow fluorescent protein. *Antimicrob Agents Chemother*. 2003;47(1):309-16.
45. van Dooren GG, Tomova C, Agrawal S, Humbel BM, Striepen B. *Toxoplasma gondii* Tic20 is essential for apicoplast protein import. *Proc Natl Acad Sci U S A*. 2008;105(36):13574-9.
46. Blume M, Nitzsche R, Sternberg U, Gerlic M, Masters SL, Gupta N, et al. A *Toxoplasma gondii* Gluconeogenic Enzyme Contributes to Robust Central Carbon Metabolism and Is Essential for Replication and Virulence. *Cell Host Microbe*. 2015;18(2):210-20.
47. Fairweather SJ, Broer A, O'Mara ML, Broer S. Intestinal peptidases form functional complexes with the neutral amino acid transporter B⁰AT1. *Biochem J*. 2012;446(1):135-48.
48. Broer S. *Xenopus laevis* Oocytes. *Methods Mol Biol*. 2010;637:295-310.
49. Wagner CA, Friedrich B, Setiawan I, Lang F, Bröer S. The use of *Xenopus laevis* oocytes for the functional characterization of heterologously expressed membrane proteins. *Cell Physiol Biochem*. 2000;10(1-2):1-12.
50. Fairweather SJ, Broer A, Subramanian N, Tumer E, Cheng Q, Schmoll D, et al. Molecular basis for the interaction of the mammalian amino acid transporters B⁰AT1 and B⁰AT3 with their ancillary protein collectrin. *J Biol Chem*. 2015;290(40):24308-25.
51. Bohmer C, Broer A, Munzinger M, Kowalczyk S, Rasko JE, Lang F, et al. Characterization of mouse amino acid transporter B⁰AT1 (slc6a19). *Biochem J*. 2005;389(Pt 3):745-51.
52. Weber W. Ion currents of *Xenopus laevis* oocytes: state of the art. *Biochim Biophys Acta*. 1999;1421(2):213-33.
53. Taylor MA, Smith LD. Accumulation of free amino acids in growing *Xenopus laevis* oocytes. *Dev Biol*. 1987;124(1):287-90.
54. Seidell A. Solubilities of Inorganic and Metal Organic Compounds: A Compilation of Quantitative Solubility Data from the Periodical Literature: Van Nostrand; 1941.
55. Box GEP, Lucas HL. Design of Experiments in Non-Linear Situations. *Biometrika*. 1959;46(1/2):77-90.
56. Jackson AJ, Clucas C, Mamczur NJ, Ferguson DJ, Meissner M. *Toxoplasma gondii* Syntaxin 6 is required for vesicular transport between endosomal-like compartments and the Golgi complex. *Traffic*. 2013;14(11):1166-81.
57. Gold DA, Kaplan AD, Lis A, Bett GC, Rosowski EE, Cirelli KM, et al. The *Toxoplasma* dense granule proteins GRA17 and GRA23 mediate the movement of small molecules between the host and the parasitophorous vacuole. *Cell Host Microbe*. 2015;17(5):642-52.
58. Fröhlich KU. Sequence Similarity Presenter: a tool for the graphic display of similarities of long sequences for use in presentations. *Comput Appl Biosci*. 1994;10(2):179-83.

Figure legends

Fig 1. Phylogenetic analysis of ApiAT family proteins.

Consensus maximum likelihood tree of ApiAT family proteins. The tree was generated from a multiple sequence alignment of 67 putative ApiAT proteins from a range of apicomplexans and chromerids, with 452 residues used in the analysis. Bootstrap values are depicted by black circles (>90% support), white circles (70-90% support), or a pink circle (60% for a group consisting of *Cryptosporidium* and chromerid proteins). The tree is unrooted. Abbreviations: Bb, *Babesia bovis*; Cp, *Cryptosporidium parvum*; Cv, *Chromera velia*; Et, *Eimeria tenella*; Nc, *Neospora caninum*; Pb, *Plasmodium berghei*; Pf, *Plasmodium falciparum*; Tg, *Toxoplasma gondii*; Tha, *Theileria annulata*; Vb, *Vitrella brassicaformis*.

Fig 2. Expression and localization analysis of *T. gondii* ApiAT family proteins.

(A-E) Western blots with anti-HA antibodies to measure the expression and molecular mass of tagged *Tg*ApiAT proteins in tachyzoites stages of the parasite. Western blots with antibodies against GRA8 and Tom40 were used to test for the presence of protein in samples where the HA-tagged *Tg*ApiAT protein was not detected. (F-I) Immunofluorescence assays with anti-HA antibodies to determine the localisation of *Tg*ApiAT proteins (green). Samples were co-labelled with antibodies against the plasma membrane marker P30 (red). *Tg*ApiAT3-3-HA-expressing parasites were co-transfected with the trans-Golgi network (TGN) marker Stx6-GFP (56), and labelled with anti-HA (red), anti-P30 (blue) and anti-GFP (green) antibodies. All scale bars are 2 μ m.

Fig 3. Genetic disruption of *T. gondii* ApiAT family proteins reveals the importance of *TgApiAT2* and *TgApiAT5-3* for parasite growth *in vitro*.

(A-F) Plaque assays depicting growth of *TgApiAT* knockout strains and their corresponding parental WT strain. 150 parasites were added to wells of a 6-well plate and cultured for 9 days in DMEM (unless otherwise indicated). (A) WT (RH Δ hxpgrt) and Δ apiAT1 parasites grown in DMEM (left) or RPMI (right). (B) WT (TATi/Tomato), Δ apiAT2 and Δ apiAT2 parasites complemented with a constitutively expressed *TgApiAT2* (c*TgApiAT2*/ Δ apiAT2). (C) WT (TATi) and Δ apiAT3 sub-family mutants. (D) WT (TATi/Tomato) and Δ apiAT5 sub-family mutants. (E) WT (TATi/Tomato) and Δ apiAT6 sub-family mutants. (F) Δ apiAT7 sub-family mutants. Note that the TATi/Tomato strain served as WT strain for the Δ apiAT2, Δ apiAT5, Δ apiAT6, and Δ apiAT7 sub-family mutants, and the identical image of the TATi/Tomato plaque assay is shown in B, D and E to facilitate interpretation of the data. All images are from the same experiment, and are representative of three independent experiments.

Fig 4. Analysis of [13 C] amino acid uptake into WT and Δ apiAT5-3 parasites reveals a role for *TgApiAT5-3* in amino acid homeostasis.

(A-B) Extracellular WT or Δ apiAT5-3 tachyzoites were incubated in medium containing [13 C]-L-amino acids for 15 min. Polar metabolites were extracted and amino acid abundance (A) and levels of [13 C]-amino acid enrichment (B) in WT (black) and Δ apiAT5-3 (red) tachyzoites determined by GC-MS. Only L-amino acids that could be detected in all experiments are shown. The data are averaged from three independent experiments and error bars represent $\pm$ s.e.m. (*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$, ****, $P < 0.0001$; Student's

t test. Where significance values are not shown, the differences were not significant; $P > 0.05$).

Fig 5. *TgApiAT5-3* is an L-tyrosine transporter that is stimulated by the presence of L-tyrosine on the *trans* side of the membrane.

(A) Time course for the uptake of [14 C]Tyr into *X. laevis* oocytes expressing *TgApiAT5-3* (squares) or into uninjected oocytes (circles). Uptake was measured in the presence of 1 mM L-Tyr. Each data point represents the mean uptake in 10 oocytes from a single experiment $\pm$ standard deviation, and the data are representative of 3 independent experiments. A first order rate equation was fitted to each time course ($R^2 = 0.97$ for *TgApiAT5-3*-expressing oocytes and $R^2 = 0.77$ for uninjected controls). Both the rate constant for [14 C]Tyr uptake and the maximal [14 C]Tyr uptake measured in *TgApiAT5-3*-expressing oocytes were significantly higher than those measured in uninjected oocytes ($P < 0.01$, Student's *t* tests). (B) *TgApiAT5-3*-expressing oocytes (squares) and uninjected oocytes (circles) were preloaded with L-Tyr by incubation in 2.5 mM L-Tyr (filled symbols) for 32 or 72 hr, respectively, or not preloaded (open symbols). Following the preincubation period, uptake of [14 C]Tyr was measured in medium containing 1 mM L-Tyr. Data show the mean uptake in 10 oocytes from a single experiment $\pm$ standard deviation, and are representative of 3 independent experiments. First order rate equations were fitted to the uptake time courses for the preloaded and non-preloaded *TgApiAT5-3*-injected oocytes ($R^2 = 0.98$ for preloaded, and $R^2 = 0.95$ for non-preloaded oocytes). Both the first order rate constants for [14 C]Tyr uptake and the maximal [14 C]Tyr uptake were significantly higher in preloaded compared to non-preloaded *TgApiAT5-3*-expressing oocytes ($P < 0.01$, Student's *t* tests). (C) *TgApiAT5-3*-expressing oocytes were preloaded by incubation in 1 mM [14 C]Tyr for 32 hr. Subsequent

efflux (filled symbols) and retention (open symbols) of the preloaded labelled substrate was measured over the time-course indicated, in the presence of an extracellular medium containing 2.5 mM L-Tyr (squares) or extracellular medium lacking of L-Tyr (circles). Data show the mean efflux and retention $\pm$ standard deviation in 3 replicates (measuring efflux/retention from 5 oocytes each) from a single experiment, and are representative of 3 independent experiments. (D) *Trans*-stimulated initial rate kinetic analysis of L-Tyr transport by *TgApiAT5-3*. The rate of L-Tyr uptake was measured at a range of [L-Tyr] concentrations in the external medium (i.e. [L-Tyr]_{cis}) in *TgApiAT5-3*-expressing oocytes preloaded with 0 mM to 2.5 mM L-Tyr (i.e. [L-Tyr]_{trans}). The *TgApiAT5-3*-mediated uptake (calculated by subtracting the uptake in uninjected oocytes from the uptake in *TgApiAT5-3*-expressing oocytes) at each [L-Tyr]_{trans} condition tested conformed to a Michaelis-Menten kinetic model ($R^2 > 0.90$ for all non-linear regressions). The data were fitted to a Scatchard linear regression ($0.89 \leq R^2 \leq 0.98$ for all linear regressions). Data show the mean uptake rate $\pm$ standard deviation in 10 oocytes from a single experiment, and are representative of 2 independent experiments.

Fig 6. *TgApiAT5-3* is an exchanger for aromatic and large neutral amino acids.

(A) *TgApiAT5-3*-expressing oocytes were pre-injected with a range of L-amino acids at a calculated oocyte cytosolic concentration of 5 mM, with the exception of L-Tyr (§) which was preloaded via incubation in 2.5 mM L-Tyr for 32 hr, or were not pre-injected (ND96). Subsequent uptake of [¹⁴C]-labelled amino acids was measured over 10 minutes and normalised to uptake per minute. Each box in the heat map shows the mean uptake in 10 oocytes from a single experiment, representative of 3 independent experiments. The statistical analyses compare pre-injected/pre-loaded oocytes to ND96 controls for each

substrate tested (*, $P < 0.05$, one-way ANOVA, Dunnet's post-hoc test. Where significance values are not shown, the differences are not significant, $P > 0.05$). (B) *TgApiAT5-3*-expressing oocytes were preloaded with a range of [^{14}C]-labelled amino acids (calculated final concentrations shown beneath each substrate), and efflux of these substrates was measured over 5 min in the absence of external amino acids (ND96) or in the presence of 5 mM external amino acids (with the exception of L-Tyr (§), which was present at a concentration of 2.5 mM), and normalised to efflux per minute. Each box in the heat map shows the mean efflux from 3 replicates (each comprised of 5 oocytes) from a single experiment, representative of 3 independent experiments. Statistical analyses compare trans substrates to ND96 controls for each efflux substrate tested (*, $P < 0.05$, one-way ANOVA, Dunnet's post-hoc test. Where significance values are not shown, the differences are not significant, $P > 0.05$).

Fig 7. *TgApiAT5-3* mediates the uptake of L-tyrosine and L-phenylalanine into *T. gondii*.

Initial rate of uptake of (A) [^{14}C]Tyr, (B) [^{14}C]Phe, and (C) [^{14}C]Arg, in WT, $\Delta\text{apiAT5-3}$, and (for A and C) *cTgApiAT5-3*/ $\Delta\text{apiAT5-3}$ strain parasites. Uptake was measured in PBS-glucose containing either 60 μM unlabelled L-Tyr and 0.1 $\mu\text{Ci/mL}$ [^{14}C]Tyr (A), 15 μM unlabelled L-Phe and 0.1 $\mu\text{Ci/mL}$ [^{14}C]Phe (B), or 100 μM unlabelled L-Arg and 0.1 $\mu\text{Ci/mL}$ [^{14}C]Arg (C). The initial rates of transport for each substrate were computed from the initial slopes of the fitted single-order exponential curves (Fig S6), and represent the mean $\pm$ SEM from three independent experiments (* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; n.s. = not significant; Student's *t* test).

Fig 8. *In vitro* growth of parasites lacking *TgApiAT5-3* is modulated by the concentration of aromatic amino acids in the growth medium, and *TgApiAT5-3* is important for parasite virulence.

(A-C) Fluorescence growth assay for WT (black) and $\Delta apiAT5-3$ (red) parasites cultured for 5 days in DMEM containing a range of L-Tyr (A), L-Phe (B), or L-Trp (C) concentrations. Growth is expressed as a percentage of maximum growth measured on day 5 for each parasite strain. For $\Delta apiAT5-3$ in (A), a sigmoidal curve has been fitted to the data. All data shown are averaged from three technical replicates (mean $\pm$ standard deviation), and are representative of those obtained in three independent experiments. The concentration of the respective L-amino acids in standard DMEM are depicted by a dashed line. (D) Five Balb/c mice were infected intraperitoneally with 1,000 RH $\Delta hxgprt$ /Tomato (black) or $\Delta apiAT5-3$ in RH $\Delta hxgprt$ /Tomato (red) strain parasites and monitored for symptoms of toxoplasmosis.

Fig 9. Model for the uptake of aromatic amino acids in *T. gondii*.

Depiction of a *T. gondii* parasite (blue) inside a host cell. Aromatic amino acids, including L-Tyr, L-Phe and L-Trp, and large neutral amino acids are thought to be translocated across the parasitophorous vacuole membrane surrounding the parasite (dashed line) through non-selective channels (57). *TgApiAT5-3* (red cylinder) functions as the major L-Tyr uptake pathway in *T. gondii*, and may also have a role in L-Trp uptake following the IFN γ -mediated depletion of this amino acid in the serum. Additionally, *TgApiAT5-3* functions as an exchanger, exporting aromatic and large neutral amino acids from the parasite, and thereby contributing to the homeostasis of these amino acids. The uptake of L-Phe and L-Trp is primarily mediated by alternate, and as yet undefined, uptake pathways (green cylinder). These alternate pathways can mediate sufficient L-Tyr uptake for parasite growth in the

1132 absence of *Tg*ApiAT5-3 at high L-Tyr concentrations (when L-Phe and L-Trp concentrations
1133 are not correspondingly high).
1134

Supporting Information

Fig S1. Multiple sequence alignment of ApiAT family proteins from apicomplexans and chromerids.

A multiple sequence alignment of the 67 ApiAT family proteins examined in this study. The alignment is presented as a “fingerprint”, where each residue is represented by a thin vertical line that has been shaded to represent the degree of conservation (as described previously; (58)). Residues with >70 % identity in the ApiAT alignment are depicted in purple, residues with 50-70 % identity are depicted in cyan, residues where > 50% of residues have similar amino acids or where amino acids are similar to residues in the above identity groupings are depicted in magenta, non-conserved residues are depicted in grey, and gaps in the sequences are white. The approximate locations of the predicted transmembrane domains are represented by numbered bars, and the location of the MFS signature sequence between transmembrane domains two and three has been highlighted.

Fig S2. Multiple sequence alignment of a selection of ApiAT family proteins from apicomplexans with human LAT3 and LAT4 proteins.

A multiple sequence alignment of ApiAT-family proteins from apicomplexans (*Tg*ApiAT1, *Tg*ApiAT2, *Pb*ApiAT8-1, *Tg*ApiAT6-1 and *Tg*ApiAT5-3) and the human LAT3 and LAT4 proteins (*Hs*LAT3 and *Hs*LAT4). Residues with >70% sequence identity are shaded in black and residues with >70% sequence similarity are shaded in gray. The red box highlights the MFS signature sequence.

Fig S3. Genetic modifications to introduce HA tags into the native loci of *TgApiAT* genes in *T. gondii*.

(A) Single cross-over recombination approach, where a vector containing a homologous flanking sequence to the target gene, in addition to a chloramphenicol resistance marker (ChlR), is introduced into *T. gondii* parasites. Single cross-over recombination results in the insertion of a HA tag into the 3' region of the open reading frame of the target gene. The approximate position of the primers used to screen *TgApiAT7-1*-HA clones are depicted. (B) CRISPR/Cas9 genome editing approach, where a guide RNA (gRNA) is designed to target a region near the stop codon of the target gene. When co-expressed with Cas9-GFP, the gRNA mediates a double-stranded break in the parasite genome near the stop codon of the target gene. The gRNA/Cas9-GFP vector is co-transfected with a donor DNA product that contains a HA tag flanked on either side with 50 bp of sequence homologous to regions immediately up and downstream of the stop codon in the target gene. Homologous repair results in introduction of the HA tag into the 3' region of the open reading frame of the target gene. (C) PCR screen to test for integration of the HA tag into the *TgApiAT7-1* locus. The presence of a 2.5 kb band that is absent from the wild type (WT) control indicates that clones 2-5 have successfully integrated the HA tag.

Fig S4. Characterisation of *TgApiAT5-3* expressed in oocytes

(A) Western blot with anti-HA antibodies on whole membrane preparations (WMP) and surface biotinylated proteins (SB) in oocytes expressing HA-tagged *TgApiAT5-3* (5-3) or oocytes that were uninjected (u.i.). (B) Efflux and retention of preloaded [¹⁴C]Tyr in uninjected oocytes. Uninjected oocytes were preloaded by incubation in 1 mM [¹⁴C]Tyr for 72 hr as described in methods. Subsequent efflux (filled shapes) and retention (open shapes)

of the preloaded labelled substrate was measured over the time-course indicated in the presence in the extracellular buffer of 2.5 mM L-Tyr (squares) or in the absence of L-Tyr (circles). Data show the mean efflux and retention in 5 oocytes from a single experiment $\pm$ standard deviation, and are representative of 3 independent experiments. (C) *TgApiAT5-3*-expressing oocytes (black) or uninjected oocytes (white) were preloaded via incubation in 2.5 mM L-tyrosine for 32 or 72 hr, respectively, as described in methods. Subsequent uptake of 1 mM [14 C]Tyr was measured in buffer where the ions were replaced as indicated. For Na⁺ replacement conditions, the replacement cation is written at the top of the respective histogram. Data show the mean uptake in 10 oocytes from a single experiment $\pm$ standard deviation, and are representative of 3 independent experiments. Uptake in *TgApiAT5-3*-expressing oocytes was not significantly different in any condition tested ($P > 0.05$, one-way ANOVA, Dunnet's post-hoc test). (D) *TgApiAT5-3*-expressing oocytes were impaled and recorded using a two-voltage clamp amplifier configuration 4-5 days post-cRNA injection. Oocytes were continuously perfused with gravity-fed ND96 buffer (pH 7.4) until otherwise indicated by the arrows in the current tracings. Top: representative current trace upon the addition of 1 mM L-Tyr at $E_m = -50$ mV or 0 mV. Bottom: representative current trace upon the change to pH 9.0 and incubation in 1 mM L-Tyr. No baselines were corrected in either tracing. Data are representative of 12 replicates.

Fig S5. Substrate specificity of *TgApiAT5-3*

(A) Uptake of 500 μ M [14 C]Tyr was measured in *TgApiAT5-3*-expressing oocytes (black) or uninjected oocytes (white) over 10 mins in presence of 500 μ M unlabelled L-amino acids. Data show the mean uptake in 10 oocytes from a single experiment $\pm$ standard deviation, and are representative of 2 independent experiments (*, $P < 0.05$, one-way ANOVA, Dunnet's

post-hoc test. Where significance values are not shown, the differences are not significant, $P > 0.05$). (B) Uptake of [^{14}C]Tyr in *TgApiAT5-3*-expressing oocytes (black) or uninjected oocytes (white) over 10 mins, where oocytes were pre-injected with uptake buffer (ND96), preloaded with 2.5 mM L-Tyr, or pre-injected with various substrate mixes, including L-amino acids (L-AA1-3), amino acid derivatives (AA derivatives 1-3), D-amino acids (D-AA), nucleosides, nitrogen bases, or sugars (see Table S2 for compositions). Data show the mean uptake in 8-10 oocytes from a single experiment $\pm$ standard deviation, and are representative of 3 independent experiments (*, $P < 0.05$, one-way ANOVA, Dunnet's post-hoc test. Where significance values are not shown, the differences are not significant, $P > 0.05$). (C) Uptake of various [^{14}C]Amino acids (at 1 mM concentration) was measured in *TgApiAT5-3*-expressing oocytes (black) or uninjected oocytes (white) over 10 mins. Data show the mean uptake in 10 oocytes from a single experiment $\pm$ standard deviation, and are representative of 3 independent experiments (*, $P < 0.05$, one-way ANOVA, Dunnet's post-hoc test, for differences between *TgApiAT5-3*-injected and uninjected oocytes for the same substrate. Where significance values are not shown, the differences are not significant, $P > 0.05$).

Fig S6. Time courses for the uptake of [^{14}C]Tyr, [^{14}C]Phe and [^{14}C]Arg in *T. gondii*.

Uptake of [^{14}C]Tyr (A), [^{14}C]Phe (B), and [^{14}C]Arg (C) in WT (A-C), $\Delta\text{apiAT5-3}$ (A-C), and *cTgApiAT5-3*/ $\Delta\text{apiAT5-3}$ (A, C) strain parasites. Uptake was measured in PBS-glucose containing either 60 μM unlabelled L-Tyr and 0.1 $\mu\text{Ci/mL}$ [^{14}C]Tyr (A), 30 μM unlabelled L-Phe and 0.1 $\mu\text{Ci/mL}$ [^{14}C]Phe (B), or 100 μM unlabelled L-Arg and 0.1 $\mu\text{Ci/mL}$ [^{14}C]Arg (C). Data points represent the mean $\pm$ SEM from three independent experiments. Lines represent fitted single-order exponential curves, from which the initial rates were calculated and depicted in Fig 7.

1230

1231 **Fig S7. Complementation of Δ apiAT5-3 strain parasites with a constitutive copy of**

1232 ***Tg*ApiAT5-3 restores parasite growth in DMEM.**

1233 Plaque assays depicting growth of TATi/Tomato (WT) parasites (top), Δ apiAT5-3 parasites
1234 (middle), and Δ apiAT5-3 parasites complemented with a constitutive copy of *Tg*ApiAT5-3
1235 (*cTg*ApiAT5-3/ Δ apiAT5-3; bottom). 500 parasites were added to 25 cm² tissue culture flasks
1236 and cultured in DMEM (left) or DMEM containing 2.5 mM L-Tyr (right) for 11 days before
1237 fixation and staining with crystal violet. Data are representative of two independent
1238 experiments.

1239

1240 **Fig S8. *T. gondii* parasites are auxotrophic for all three proteinogenic aromatic amino**

1241 **acids.**

1242 Fluorescence growth assays measuring the growth of WT (black) and Δ apiAT5-3 (gray)
1243 parasites in DMEM containing different concentrations of L-Tyr (A), L-Phe (B) and L-Trp
1244 (C). The growth of parasites is expressed as a percentage of the optimal concentration for
1245 each amino acid tested in each parasite strain, and was measured at mid-log phase for this
1246 optimal concentration (5 days post-inoculation). Parasite growth was determined using the
1247 same amino acid concentrations used in Fig 8, but included a 0 mM concentration (which
1248 was not possible to depict in Fig 8 because of the log scale on the x axis). For simplicity, only
1249 the following amino acid concentrations are depicted in this figure: 0 mM, 0.423 mM and 2.5
1250 mM L-Tyr (A), 0 mM, 0.32 mM and 10 mM L-Phe (B), and 0 mM, 0.063 mM and 1 mM L-
1251 Trp (C). The data for 0.423 mM L-Tyr (the normal DMEM concentration of L-Tyr) were
1252 interpolated from curve fitting while 0.32 mM L-Phe and 0.063 mM L-Trp (the nearest tested

concentrations to those present in DMEM) were experimental data points. Data represent the mean $\pm$ SEM from three independent experiments.

Fig S9. Preliminary characterisation of the Δ apiAT5-3/RH Δ hxgprrt/Tomato mutant

(A) Uptake of [14 C]Tyr in RH Δ hxgprrt/Tomato (WT, blue) and Δ apiAT5-3 in RH Δ hxgprrt/Tomato (red) parasites. Uptake was measured in PBS-glucose containing 60 μ M unlabelled L-Tyr and 0.1 μ Ci/mL [14 C]Tyr. Data points represent the mean from a single replicate. Lines represent fitted single-order exponential curves. (B) Fluorescence growth assay for Δ apiAT5-3/RH Δ hxgprrt/Tomato parasites cultured for 16 days (when parasites were in mid-logarithmic stage) in DMEM containing a range of L-Tyr concentrations. Growth is expressed as a percentage of maximum growth measured on day 16, and data points represent the mean from three technical replicates ($\pm$ standard deviation) in a single experiment. The concentration of L-Tyr in standard DMEM is depicted by a dashed line. (C) Plaque assays depicting growth of RH Δ hxgprrt/Tomato (WT) parasites and Δ apiAT5-3/RH Δ hxgprrt/Tomato parasites in normal DMEM (top) or DMEM containing 2.5 mM L-Tyr. 1000 parasites were added to each 25 cm² tissue culture flask and incubated for 8 days (left and centre) or 18 days (right) before developing. Data are from a single independent experiment.

Fig 1






Fig 2


A




B




C




D




E




F



G



H



I




Fig 3

bioRxiv preprint doi: <https://doi.org/10.1101/306993>; this version posted April 26, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.


A

RHΔxpr
(DMEM)

ΔapiAT1
(DMEM)

ΔapiAT1
(RPMI)

ΔapiAT1
(RPMI)




B

TATi/Tomato

ΔapiAT2

ΔapiAT2/
cTgApiAT2




C

TATi

ΔapiAT3-1

ΔapiAT3-2

ΔapiAT3-3




D

TATi/Tomato

ΔapiAT5-1

ΔapiAT5-2

ΔapiAT5-3




E

TATi/Tomato

ΔapiAT6-2

ΔapiAT6-3



F

ΔapiAT7-1

ΔapiAT7-2






Fig 4**A****B**





Fig 5**A****B****C****D**





Fig 6**A****B**

Fig 7

A



B



C








Fig 8**A****B****C****D**

Fig 9

